Published in final edited form as:

ACS Infect Dis. 2018 August 10; 4(8): 1162–1178. doi:10.1021/acsinfecdis.8b00023.

A comparison of optical, electrochemical, magnetic, and colorimetric point-of-care biosensors for infectious disease diagnosis

Oleksandra Pashchenko[†], Tyler Shelby[†], Tuhina Banerjee[†], Santimukul Santra^{†,*}

[†]Department of Chemistry, Pittsburg State University, 1701 South Broadway Street, Pittsburg, Kansas, 66762;

Abstract

Each year, infectious diseases are responsible for millions of deaths, most of which occur in the rural areas of developing countries. Many of the infectious disease diagnostic tools used today require a great deal of time, a laboratory setting, and trained personnel. Due to this, the need for effective point-of-care (POC) diagnostic tools is greatly increasing with an emphasis on affordability, portability, sensitivity, specificity, timeliness, and ease of use. In this review article, we discuss the various diagnostic modalities that have been utilized towards this end and are being further developed to create POC diagnostic technologies, and we focus on potential effectiveness in resource-limited settings. The main modalities discussed herein are optical-, electrochemical-, magnetic-, and colorimetric-based modalities utilized in diagnostic technologies for infectious diseases. Each of these modalities feature pros and cons when considering application in POC settings, but overall reveal a promising outlook for the future of this field of technological development.

Graphical Abstract

*Corresponding Author: Department of Chemistry, Pittsburg State University, 1701 S. Broadway Street, Pittsburg, KS 66762, USA. ssantra@pittstate.edu.

The authors declare no conflict of interest.

Keywords

point-of-care; infectious diseases; diagnosis; detection; biosensors

In the fight against infectious diseases, reaching an accurate and timely diagnosis is often important in order to make an informed decision about the treatment plan. A rapid and accurate diagnosis allows clinicians to prescribe the proper medical treatment and greatly improves patient prognosis overall. When dealing with infectious diseases in particular, a timely diagnosis is even more crucial and may reduce or prevent further infection within the patient population. World Health Organization (WHO) has emphasized the importance of creating POC tests and created a set of criteria for evaluating POC tests. These criteria are summarized by the acronym ASSURED (Affordable, Sensitive, Specific, User-Friendly, Robust and rapid, Equipment free, Deliverable), which represents the characteristics needed for an ideal POC platform.¹⁻³ Despite the attention given to the development of novel diagnostic and treatment methods, infectious diseases continue to pose a major threat to the global population.⁴⁻⁷ Respiratory infections such as pneumonia, influenza, and tuberculosis remain some of the most prolific causes of infectious disease deaths, resulting in nearly 5 million reported deaths each year. This is roughly twice as many as the reported HIV/AIDS-related deaths (2.5 million deaths annually). Malaria and diarrheal diseases account for an additional 1.2 and 2.2 million deaths, respectively, each year.⁸⁻¹⁰ Overall, infectious diseases caused by bacteria, viruses, parasites and fungi result in 15 million deaths each year, and approximately 95% of these deaths occur in low- to middle-income countries.^{8,11}

While there are many effective methods for the detection of pathogenic agents, such as culturing, microscopy, genomic amplification (e.g., PCR) and immunoassays (e.g., ELISA), these approaches each have their own shortcomings and are less applicable in resource-limited settings where infectious diseases are more prevalent. Culturing is a very lengthy process, often requiring multiple days or weeks to produce results, in which time the

infection can advance within the patient and be transmitted throughout the population. Furthermore, the empirical use of antibiotics is commonly pursued while bacterial culture results are pending, which risks increasing the prevalence of antibiotic resistant bacteria. While more efficient with regards to time, microscopy is limited in both scope and application in POC settings, as it is restricted to pathogens able to be visualized at low magnification.^{4,8,12}

Further diagnostic methods such as polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay (ELISA) are more efficient with regard to time and scope but have several drawbacks. Immunoassays can be successfully utilized to detect infectious diseases if the correct antibody-antigen interaction is determined but are difficult to develop and use for the detection of pathogens with high rates of epitope mutation. Additionally, PCR and ELISA often require the use of expensive laboratory equipment and trained professionals.^{13–15} Unfortunately, there are many regions of the world in which this environment is simply not available or sustainable. Due to this, it is common for biological samples to be collected and transported to the nearest laboratory facility or hospital capable of performing such complex laboratory procedures, often a great distance away. Once delivered, lab results are obtained, and the results are sent back, often days or weeks later. After receiving the results, the physician must then contact the patient in order to begin proper treatment. The inefficiency of this protocol calls for the development of alternative POC diagnostic methods that may be used in smaller, regional medical clinics that do not have the capabilities for traditional diagnostic techniques. To be effective, these methods must be timely, cost-effective, relatively simple, and reasonably portable.¹⁶

Recently, a number of diagnostic platforms have been developed to detect pathogenic biomarkers (DNA/RNA, glycoproteins, enzymes, antibodies, etc.) with the aforementioned qualities, such as speed, simplicity and cost-effectiveness.^{1,17} These biosensors are often based on nano- or micro-technology platforms and they commonly rely on the production of optical, electrical, magnetic or visually detectable signals. Positive detection signals are produced when the sensors encounter pathogens or pathogen byproducts. While the mechanisms used to produce positive signals vary, the goal remains the same across the board: sensitive and timely detection of infectious pathogens. Many of these platforms are undergoing further optimization for use in POC settings, with the goal of being able to detect the desired biomarker within one hour. In many countries patients do not live with nearby access to health care, and it is often not feasible for them to come in on two separate days, one to provide a biological sample and second time to collect results and begin treatment. Additionally, many live far enough away that they may rarely travel to locations with health care access, therefore diagnostic techniques must be created that can be brought to the patient. While there are several POC diagnostic tools widely used today in the community and clinics with minimal laboratory capabilities, only a small handful of infectious diseases can be detected currently. These include malaria with Binax NOW, tuberculosis (TB) with Xpert MTB/RIF, and HIV with several different lateral flow assays among others. Furthermore, the use of smartphone-based diagnostics is increasing such as MobiNAAT recently designed to detect *Chlamydia trachomatis*.^{2,18–23}

There are many difficulties in developing POC diagnostics that are realistically applicable. In order to increase the number of effective POC diagnostic tools, additional biosensors must be developed with certain capabilities in mind. Firstly, they must be able to detect biomarkers in trace quantities and in complex media such as blood, sputum, or environmental samples, such as food and/or water. Further difficulties arise when considering the complex pathogenesis undergone by many infectious agents, such as bacteria, viruses, or parasites. Certain pathogens may remain in the blood or sputum longer than others and may only produce certain biomarkers at specific stages in their life cycle. For this reason, optimal biosensors are those that can be customized for more than just one biomarker, allowing them to detect multiple pathogens throughout various stages in their life cycle. Furthermore, POC diagnostic techniques aim to be easily utilized with minimal training in a setting that cannot support a full laboratory.

Despite these significant hurdles, much progress has been made in this field. However, realistic implementation is not always the focus of many developing diagnostics, and it is the goal of this paper to outline various novel POC platforms that may soon move from the lab into clinical settings. The biosensors discussed herein are divided into categories based upon the modality used for detection. The ASSURED criteria are often not reported for diagnostic platforms in early development, so those discussed herein are evaluated based on critical POC characteristics such as level of detection (LOD), timelines, cost, detection capabilities in complex media, and other factors relating to the effectiveness of the platforms in resource-limited-settings.

Detection Modalities

There are many different approaches to developing diagnostic platforms, but in this paper the focus will be on the development of optical-, electrochemical-, magnetic-, and colorimetric-based modalities. Furthermore, there are many different techniques that fall under the modalities listed, but a few of the most commonly studied techniques are highlighted within each section with everything else grouped under the category of *other*. An outline of the various infectious diseases that have been successfully detected in a number of studies can be found in Tables 1–4, with a few described in further detail in the rest of this work.

Optical Detection

Optical-based detection of infectious diseases has been utilized in several attempts to design ideal POC platforms. While this modality has shown great potential, there are several pros and cons to be considered. Optical-based diagnostics rely on the sensitive detection of photon emission from dyes and molecules that are excitable by light. Often, fluorescent probes are designed which will only emit photons after interacting with targeted biomarkers, such as antibodies, antigens, or genomic material.^{24–26} Compared to other visualization techniques such as microscopy or enzyme-based detection, fluorescence emission allows increased sensitivity, adding to the reliability of this modality. Additionally, there are a wide variety of molecules that have intrinsic fluorescence qualities, which is one of the benefits of this technique that allows some degree of platform customization. However, intrinsic

fluorescence properties of non-target molecules may also cause background noise and false positives, therefore this method usually requires somewhat clear sample solutions to prevent interference from other molecules.^{24,25} While there are many pros to using optical-based platforms, they often require technology not commonly found in resource limited settings such as filter fluorometers or spectrofluorometers, which increase the platform cost and complexity, and often limit its application in resource-poor settings.^{25,27} However many POC modalities being developed are overcoming this issue by combining optical-based technologies with smartphones to create more portable technologies.²⁸ Finally, if this approach is used in immunoassays, many fluorescence molecules utilized as probes may interfere with the binding of antibodies to the antigen, which could prevent this platform from being used with the detection of certain diseases.²⁵ Additionally, it is critical to control where the fluorescence molecule binds to prevent the antigen binding site from being occupied by the fluorescence molecule, this can be difficult in many cases.²⁷

Optical Detection Utilizing Fluorescence Polarization

A commonly used fluorescence assay, fluorescence polarization (FP), involves the fluorescent tagging of a probe which is then allowed to interact with target molecules, resulting polarized light emission.^{25,27,29–31} FP is preferable to many other fluorescence based immunoassays because little sample preparation is needed.^{27,32} This assay was utilized in several studies to detect influenza,³³ *Mycobacterium tuberculosis*,^{34–36} *Salmonella spp.*,³⁰ and *Brucellosis spp.*³⁷ Walker et al. was able to detect *M. tuberculosis* in about 3 hours at levels as low as 1 TB genome. Later, they were able to make this test more rapid but slightly less sensitive and were able to detect 10 TB genomes in 20 minutes.^{34,36} FP was utilized by Ki Soo Park et al.³⁰ for specific detection of *Salmonella spp.*, as well as differentiation between different sub-types of *Salmonella* such as *S. typhimurium* and *S. paratyphimurium*. In blood samples, the bacterial detection reached a sensitivity of about 1 CFU/mL in less than 3 hours. They utilized a PCR based approach with DNA polymerase, complementary DNA to the target STY3007 and STY1121 genes in *Salmonella spp.*, and a reporter probe conjugated with a single fluorophore. When mixed with a sample of *Salmonella spp.*, the complementary DNA bound to the target genes and the free reporter probe emitted a high signal in an FP assay. On the other hand, when the target *Salmonella spp.* genes were not present in the sample, the DNA polymerase catalyzed the cleavage of the fluorophore from the reporter probe, resulting in low values in the FP assay. They calculated the cost of this test to be about \$1 per test. This rapid and low-cost design shows great potential for use as a POC platform. However, because this assay requires the detection of intracellular components, additional sample preparation steps are required, such as DNA extraction in this case.

Optical Detection Utilizing Quantum Dots

Quantum Dots (QDs) are very small nanoparticles that act as semi-conductors that have strong fluorescence properties. QDs have been utilized to develop infectious disease diagnostic platforms in several studies.^{38–40}

Kenshin Takemura et al.⁴¹ demonstrated a detection limit of 0.4pg/mL for H1N1 influenza utilizing CdSeTeS QDs. In another study done by Kevin Ming et al.⁴² a quantum dot-based

detection platform was combined to develop a portable smartphone diagnostic tool for HIV and hepatitis B with a detection limit of 1000 viral genetic copies/mL and in less than 1 hour.

Another interesting application of fluorescence-based detection is demonstrated by Xiong et al. Functionalized *Staphylococcus aureus* cells with fluorescence were turned into nanobioprobes capable of targeting and detecting pathogens.⁴³ Targeting is made possible through interactions between protein A which is expressed on the surface of *S. aureus*, and Fc region of selected monoclonal antibodies (mAbs). Since this assay targets surface proteins, minimal sample preparation is needed. These mAbs may be used to target any selected virus or bacteria, however this study was conducted by specifically detecting H9N2 avian influenza virus. The conjugation of antibodies to the surface of these cellular nanobioprobes does not require conjugation chemistry, as the Fc region of the antibodies and protein A have a strong binding affinity. Addition of the fluorescent modality is accomplished by synthesizing CdS_{0.5}Se_{0.5} within the cell. When mixed with targeted viral glycoproteins, these nanobioprobes and immunomagnetic beads formed a sort of “sandwich” around the viral glycoprotein. The magnetic beads allow for the capture of the pathogen while the nanobioprobes allow for its detection and subsequent quantification. As the concentration of the targeted viral glycoprotein decreased, the fluorescent signal responded accordingly, and the detection limit determined using this method was 8.94 ng/mL of targeted viral glycoprotein. The true strength of this technique is its ability to be easily targeted against multiple pathogens, due to the simplicity with which mAbs may be targeted to the *S. aureus* surface with no need for conjugation chemistry. These nanobioprobes also provide an approach to biosensor development using a functionalized organism, reducing environmental risks of toxicity often encountered when using inorganic nanomaterials. However, because these nanobioprobes are created with live bacteria it may be important to handle them with caution. Also, due to the potential mutations and variation in bacteria the consistency of these products may be reduced.

Optical Detection Utilizing Microfluidic Platforms

Several other studies have utilized optical based detection methods along with a microfluidic platform. Microfluidic technology has allowed for the creation of disposable, miniaturized devices that combine various steps into a compact space. Microfluidic devices can be customized to do DNA amplification, sample preparation, and detection all in one chip.^{17,40,44–46} Researchers have demonstrated the detection of *Escherichia coli*,^{47,48} *S. aureus*,⁴⁷ BK virus,⁴⁹ Dengue,^{50–52} avian influenza virus,⁴⁶ *Streptococcus pneumoniae*,⁵¹ and *S. typhimurium*.⁵³ Furthermore, one study utilized optical properties along with microfluidic technology to detect *Chlamydia trachomatis* and *Neisseria gonorrhoeae* at levels as low as 300 CFU/mL and 1500 CFU/mL respectively.⁵⁴ Edwar Iswardy et al.⁵⁰ utilized a dielectrophoresis chip with anti-flavivirus antibody coated bead to detect dengue virus. They reached detection times of about 5 minutes and the chip was reusable for more than 50 times. This rapid and low-cost platform demonstrates potentials of this microfluidic chip as a POC diagnostic tool.

Optical Detection with Other Nanotechnologies

Some studies are combining nanotechnology with fluorescent molecules to create diagnostic platforms as was done in the study done by Banerjee et al.⁵⁵ to detect *E. coli*. Other studies utilize the inherent optical properties, surface plasmon resonance (SPR), of gold nanoparticles (AuNPs).^{39,56} Diagnostic techniques utilizing AuNPs have been studied for the detection of *M. tuberculosis*,⁵⁷ Influenza,⁵⁸ and *S. aureus*.⁵⁹ In the study done by Yu, Mengqun et al.⁵⁹ a fluorescence resonance energy transfer platform was utilized to detect *S. aureus* detecting as low as 10 CFU/mL in under 30 minutes.

Electrochemical Detection

Electrochemical detection is currently being studied for potential POC diagnosis of infectious diseases. This is one of the most common modalities being researched and developed due to the potential for miniaturization, portability, and cost reductions.^{26,27} The glucometer is the most common example that utilizes this modality.^{62,63} Electrochemical detection modalities utilize biosensors that are capable of binding to a target molecule associated with the disease. When these probes bind to the target molecule, they undergo a conformational change and create a small current that can be detected. Unlike fluorescence-based detection, this modality is more easily utilized with non-clear samples such as blood.²⁴ Additionally, electrochemical-based detection doesn't require complex optical instrumentation that is used in many fluorescence-based detections. Electrochemical-based detection often uses instrumentation such as carbon electrodes and field effect transistor (FET) biosensor along with electrochemical analysis methods such as with differential pulse voltammetry (DPV) platforms. Some instrumentation has been made very portable, such as the hand held potentiostat. While these methods can be initially costly and complicated to utilize, the technology can evolve into more miniaturized and easy to use platforms as the development progresses.^{24,44,57,64–67}

Electrochemical Detection Utilizing Field Effect Transistors

Additionally, various strains of avian influenza were detected using FET sensors with great success.^{66,68} The FET method has shown promise due to its portability, sensitivity, and ease of use.⁶⁹ Hideshima et al.⁶⁶ developed a FET biosensor capable of detection viral proteins within the attomolar concentration. Ultimately, the developed FET biosensor was able to detect and differentiate between H1 and H5 in attomolar concentrations, which means that this device is capable of detecting a single viral particle, since each viral particle displays roughly 500 hemagglutinin particles on its surface. Bovine Herpes Virus-1 was detected using FET biosensors in under 10 minutes, this method could be utilized with other infectious diseases.⁷⁰ Furthermore, Savannah Afsahi et al.⁷¹ utilized similar FET methods to detect zika with concentrations as low as 450 pM in about 5 minutes.

Electrochemical Detection Utilizing Microfluidic Platforms

Microfluidic chips that utilize electrochemistry have become a popular choice for the development of POC diagnostic tools due to their sensitivity, portability, speed, and ease of use.^{63,72,73} Several studies have utilized a microfluidic platform along with electrochemistry to detect *Streptococcus mutans* and *Pseudomonas aeruginosa*,⁷⁴ several strains of avian

influenza,^{44,75,76} *Salmonella* spp.,⁴⁴ cholera toxin,⁷⁷ *M. tuberculosis*, *Haemophilus influenza*, and *K. pneumonia*.⁷⁸ In the study done by Hsieh et al.⁴⁴ researchers utilized a DNA probe with a redox reporter bound to a microfluidic chip. When complementary target DNA binds to the DNA probe, it undergoes a conformational change causing a change in the redox rate of the reporter which creates a current that can be detected. This biosensor cannot detect DNA levels naturally found in the blood, so PCR or loop mediated isothermal amplification (LAMP) is necessary to amplify the DNA. This study integrated LAMP into microfluidic chip to create a microfluidic electrochemical quantitative LAMP (MEQ-LAMP) device shown in Figure 1, in order to decrease cost and detection time in addition to decreasing the instrumentation needed for the detection. The MEQ-LAMP chip successfully detected *Salmonella* spp. at levels as low as 16 copies of DNA in under 50 minutes. Combining the preparation, amplification, and detection in one multiplex platform is a step towards an ideal POC platform.

Electrochemical Detection Utilizing Nanotechnology

Several studies utilized nanotechnology along with electrochemistry to increase sensitivity levels in the detection of several infectious diseases.^{80,81} These methods have been utilized to detect influenza,⁶⁵ *M. tuberculosis*,^{64,82} *Clostridium difficile*.⁸³ One study utilized electrical signals to detect influenza virus particles using silver nanoparticles and was designed by Sepunaru et al.⁶⁵ Silver nanoparticles are first adsorbed onto the virus surface when present together in solution. Upon the addition of a carbon electrode to the solution, current spikes are observed which correlate with the oxidation of the adsorbed nanoparticles. This method produces current spikes which are proportional in magnitude to the concentration of the virus in solution and may therefore be used to quantify viral levels as well as detect the pathogen. While this method is not able to determine the specific viral species, it is able to differentiate between viral and bacterial infections in a simple, POC applicable manner.

Another example of the utilization of electrochemical-based detection of *M. tuberculosis* with AuNPs is demonstrated by Benjamin Ng et al.⁶⁴ This assay took advantage of the high binding affinity between streptavidin (SA) and biotin. *M. tuberculosis* DNA was extracted from *M. tuberculosis* cells and then isothermally amplified with biotin dUTPs to create a biotinylates product and then placed on a SA-coated disposable screen-printed carbon electrode (SPCE). AuNPs are conjugated with streptavidin and washed with BSA/PEG buffer; the BSA binds to any areas left exposed on the AuNPs to prevent unwanted interactions. Finally, these conjugated AuNPs are added to the SPCE, and the more AuNPs are bound to the SPCE, the higher the DPV signal indicating a positive result. Concentrations as low as 1 CFU of *M. tuberculosis* DNA were detected. Additionally, this assay was tested with a handheld potentiostat which can be used at POC sights because it can be powered by a laptop. The total cost per assay was about \$10, and it could be completed in under 90 minutes.

Other Electrochemical Detection Methods

Impedance based electrochemical biosensors were used to detect Flaviviruses such as dengue and zika,⁸⁴ influenza,⁸⁵ HIV,⁸⁶ and *E. coli*.⁸⁷ Various electrochemical methods were

also utilized to detect several bacterial strains such as *M. Tuberculosis*,^{88,89} *E. coli*,⁹⁰ and *Vibrio cholera*.⁹⁰ Another study utilized various electrochemical methods to detect HIV using microelectrode arrays.⁹¹

While detecting infectious diseases has been on the front lines of many research studies, identifying infectious disease resistance is just as important. In one study thin film transistor sensors were developed by Chunxiao Hu et al.⁹² to detect antimicrobial resistance genes for *E. coli* and *Klebsiella pneumoniae*. This method detected 100 copies of the genomic DNA in under 3 minutes.

Magnetic Detection

Magnetic detection of infectious disease agents utilizing magnetic nanoparticles (MNPs) is a growing field. This approach usually utilizes binding affinities between conjugated antibodies on MNPs and the target pathogen. There are two popular uses of MNPs for the detection of infectious diseases. The first utilizes the magnetic relaxation properties of the MNPs when they interact with water. MNPs conjugated with antibodies are placed in solution with the target pathogen and bind to one another, causing aggregates. This aggregation alters the spin-spin-spin relaxation time (T₂) of the surrounding water protons which can be quantified by a magnetic resonance spectroscopy machine.^{4,96–100} The second utilizes magnetoresistive sensors (Figure 2). In this method, the antibody is fixed to a surface and the sample with the pathogen antigen is washed over it, resulting in binding. Then, MNPs conjugated with the antibody are washed over the same surface and bind to the antigen as well. This second binding of the MNPs alters the magnetic field and gives off an electrical signal that can be detected.^{38,96,101,102} Many of these assays are very rapid and take less than an hour for detection. Magnetic-facilitated detection is especially appealing for POC settings due to the nanoparticle's ability to be manipulated in a magnetic field, which can decrease sample preparation time by utilizing magnetic field separation. Additionally, magnetic nanoparticle detection can provide signals in opaque samples such as blood, making this modality superior to light- and visual-based modalities in these cases. Furthermore, biological samples usually do not have ferromagnetism properties. This leads to very minimal background noise, which is commonly found with fluorescence detection methods.¹⁰³ One draw-back to most magnetic nanoparticles such as iron oxide MNPs is that they do not possess intrinsic photophysical properties that many other nanoparticles possess, such as gold.^{38,104} While the assays are relatively inexpensive to run, the instrumentation needed is not very portable and can be expensive.³⁸

While magnetic-based infectious disease detection methods are less commonly studied, there have been a few promising studies conducted that have successfully detected several common infectious diseases, and many of these studies can be adapted to detect many other types of infectious diseases as well.

Magnetic Nanoparticles

Magnetic nanoparticles have been utilized in several studies to create potential POC diagnostic platforms for the detections of *E. coli*,^{55,105} influenza,¹⁰⁶ *S. typhimurium*, *S. aureus*,¹⁰⁵ and anthrax.¹⁰⁷

Using superparamagnetic iron oxide nanoparticles, Shelby et al.¹⁰⁶ designed biosensors capable of detecting and differentiating between influenza glycoproteins. The nanoparticle platform used in this approach is based upon a magnetic iron core surrounded by a polyacrylic acid coating. This coating provides stability in addition to the ability to functionalize the nanoparticle via conjugation of targeting molecules, such as mAbs. These molecules allow the nanoparticle to interact in a specific fashion with the desired pathogenic targets, which can then be observed by the collection of sensitive T2 data. In one study, these magnetic relaxation nanosensors (MRnS) were used to detect influenza glycoproteins (H1 and H5) in the nanomolar concentration. In addition, MRnS were able to differentiate between these glycoprotein variants, and could therefore be used to distinguish between influenza subtypes. Furthermore, detection of viral contaminants was accomplished within 30 minutes, is simple and relatively portable, requiring only a bench-top magnetic relaxometer for sample analysis. The MRnS are also stable and cost-effective to produce, making this approach a worthy candidate for POC diagnostics.

In an additional study conducted by Banerjee et al.,⁵⁵ this same iron oxide platform was further functionalized with a fluorescent modality, allowing for the detection of pathogenic *E. coli* using both magnetic and fluorescent analysis. In this approach, the polyacrylic acid coating was loaded with fluorescent dyes. Following the collection of magnetic relaxation data, bacterial pellets are isolated via centrifugation, resuspended, and analyzed via fluorescence as shown in Figure 3. These magneto-fluorescent nanosensors (MFnS) were able to detect as little as 1 CFU of the desired pathogen (*E. coli* O157:H7) and were able to distinguish between other *E. coli* species, as well as heat-inactivated *E. coli* O157:H7. To further test the realistic effectiveness of MFnS, they were tested in complex media such as milk and lake water, and produced similar results, detecting as little as 1 CFU of the desired pathogen within 30 minutes.

Magnetoresistive Sensors

Chih-Cheng Huang et al.¹⁰⁸ have been working on developing an immunoassay based POC diagnostic platform with a giant magneto resistive biosensor. This technique is also being utilized for the diagnosis of TB with a detection limit of 104 cells/mL of BCG bacteria.¹⁰⁹ Krishna Venkatramana et al.¹⁰³ designed a magnetoresistive platform capable of detecting Influenza A virus. A magnetoresistive biosensor chip was designed and functionalized to easily bind amino groups. Influenza A antibodies were fixed to the biosensor and a sample with influenza A virus was added and allowed to bind. Next, biotinylated antibody was added and allowed to bind to the antigen, and the MNPs were washed over the top and bound to the biotin. Therefore, the number of MNPs was proportional to the amount of influenza A present. A bench-top system was used to detect the changes in magnetic field through a current. This assay detected viral concentrations as low as 1.5×10^2 TCID₅₀/mL, which is more sensitive than ELISA. Furthermore, the magnetoresistive chip contains 64 sensor arrays which would allow the potential to conjugate various antibodies and detect different subtypes of virus or even various pathogens in a single assay. While the assay requires time and is somewhat complicated to perform, Venkatramana foresees the possibility of the assay being further developed into a handheld device.

Other Magnetic-Based Detection Methods

Although not as common in infectious disease diagnosis, AC susceptometry has been utilized in some studies. AC susceptometry along with LAMP was utilized by Bo Tian et al.¹¹⁰ to detect synthetic zika oligonucleotides at levels of 1 aM in 20% serum in about 27 minutes.

Additionally, there have been several other optomagnetic studies that have been demonstrate as well. The detection of *V. cholera* was demonstrated by Rebecca S. Bejhed et al.¹¹¹ detecting levels of 5 pM in under 20 minutes. Finally, in another study done by Bo Tian et al,¹¹² *Salmonella* was detected using a blu-ray optomagnetic method at levels as low as 8E4 CFU/mL in under 3 hours.

Kim Jeonghyo et al.⁵⁷ utilized both magnetic properties and photophysical properties of nanoparticles to detect TB. Magnetic microparticles (MMPs) bought from Invitrogen and synthesized AuNPs were conjugated with two different antibodies that recognize the CFP-10 antigen found in the early stages of TB. The conjugated MMPs and AuNPs aggregated with the CFP-10 antigen to create a type of sandwich, which could then be removed using a neodymium-iron-boron magnet. The absorbance of the remaining AuNPs was then inversely correlated with the concentration of CFP-10 antigen present. Levels as low as 1.8 pg/ml were detected using this method in under an hour. This level of sensitivity and speed, along with the assay's ease of operation and low cost (\$2 per assay), make this platform another potential candidate for ideal POC detection. Furthermore, the instrumentation used to run these assays costs roughly \$300, which is relatively cost-effective when compared to other laboratory equipment start-up costs.

Finally, a magnetic-based diagnostic technique for *S. aureus*¹¹³ was created with detection levels as low as ten bacteria in a 10- μ l sample in under 15 minutes. Other magnetic-based detection methods for infectious diseases such *M. tuberculosis*^{57,114} and dengue¹¹⁵ have also shown promising results with a level of detection of 1E3 cells/mL for *M. tuberculosis* and 100 pg/ml for dengue.

Colorimetric and Lateral Flow Tests

One of the main goals of POC diagnostic research is the development of assays that do not rely on microscopes, relaxometers, a consistent supply of electricity, or expensive and bulky machinery. Towards this end, a number of assays have been developed that ideally allow the collection of detection results using the naked eye or minimal detector technologies, and often rely on colorimetric modalities or sedimentation. Lateral flow assays (LFA) are one such example and have been utilized for pregnancy tests and HIV tests. For this test, a nitrocellulose, nylon, paper, or other composite membrane is usually used in an antigen capture assay. These membranes are capable of capillary action, and therefore are self-sufficient. Labeled antibodies are bound to the membrane and the antigen sample is allowed to diffuse along the membrane. When the antigens bind to the labeled antibodies this results in a color change in the colorimetric molecule being used. This change can be visualized with the naked eye or with minimal assistance. These types of diagnostic techniques are very attractive because they often utilize very little to no instrumentation, are cost-effective, rapid,

and can be easily interpreted with minimal training. On the down side, this technique is solely quantitative and cannot indicate the severity of the infection.^{4,25,117,118}

Lateral Flow Detection

While there is a current urine lateral flow test on the market used to detect active TB in HIV-positive adults, it lacks required levels of sensitivity to be fully effective in clinical scenarios.^{119–121} In a different study, Jesus M. Gonzales et al.¹²² developed a lateral flow test that may be more applicable to POC settings using immunodominant epitopes derived from highly immunogenic *M. tuberculosis* cell-wall proteins. In this technique, peptides were conjugated to BSA and were used along with colloidal gold particles on nitrocellulose membrane to detect antibodies of TB patients. The prototype utilized a combination of 3 different peptides and had a specificity greater than 90%. This assay was able to determine positive/negative status within roughly 15 minutes and had minimal reaction towards latent TB and BCG vaccinated patients.

Thao T. Le et al.¹²³ continued to develop their avian influenza detection into a lateral flow test prototype. They were able to differentiate between various strains of H3N2 and detect levels as low as 2E6 virus particles utilizing the more specific aptamers rather than antibodies along with gold nanoparticles in their dual recognition element lateral flow assay (DRELFA) approach. They compared this approach to the antibody-based LFA to show the superiority of DRELFA to the more common LFA approach (Figure 4). The high portability and ease of use of a lateral flow test makes this a potential POC diagnostic test.

Furthermore, a study conducted by Seon-Ju Yeo et al.¹²⁴ demonstrated the use of a lateral flow assay in conjunction with a light weight fluorescence reader connected to a smart phone for the detection of H5N1 avian influenza. A nitrocellulose strip was prepared with anti-influenza antibodies fixed to the test line on the membrane, and anti-mouse IgG antibodies were fixed to the control line. A bioconjugate was also created which consisted of anti-influenza antibodies conjugated to coumarin-derived dendrimers, which acted as the fluorophore. The bioconjugate and the sample with H5N1 viral particles were allowed to diffuse down the strip and the H5N1 particles bound to the test line while the bioconjugate bound to the H5N1, creating a sandwich type interaction. This assay is demonstrated in Figure 5. The fluorescence intensity on the test and control lines was then quantified using the smart phone detector. This assay reached sensitivity levels of 97% and detected H5N1 in about 15 minutes. In addition to these rapid and sensitive characteristics, the high portability of this device makes it a potential POC tool for the diagnosis of H5N1.

Utilizing lateral flow assays several studies were able to detect several other infectious diseases such as *Enterococcus faecalis*, *S. aureus*,¹²⁵ *Listeria monocytogenes*,¹²⁶ *Shigella*,¹²⁷ Dengue, Yellow Fever, Ebola,¹²⁸ and *Leptospirosis*.¹²⁹ The *E. faecalis* and *S. aureus* lateral flow tests were successfully developed by Li Wang et al.¹²⁵ which could be utilized in about 75 minutes, detecting levels as low as 710 CFU/mL for *E. faecalis* and 680 CFU/mL for *S. aureus*.

Other Colorimetric Detection Methods

In addition to lateral-flow assays, aggregation and sedimentation-based diagnostic techniques also allow for naked-eye detection. These methods often involve the use of particles which change in color when aggregated, such as gold nanoparticles, or the use of natural coagulants which result in visual sedimentation. Some such studies have developed rapid visual detection of bacteria and viruses such as enterovirus 71,¹³⁰ hepatitis B,^{131,132} hepatitis C,¹³² papillomavirus,¹³⁰ *M. tuberculosis*,^{122,133,134} avian and human influenza,^{124,135} zika, chikungunya, and dengue.¹³⁶ Another study utilized engineered phages for colorimetric detection of *E. coli*.¹³⁷

One study visually detected *M. tuberculosis* in 2 hours with a cost of \$0.35 per test.¹³⁴ Furthermore, Jerney D. Driskell et al.¹³⁸ utilized a similar technique using AuNPs with dynamic light scattering to detect the influenza virus <100 TCID₅₀/mL in under 30 minutes. Another detection method for influenza was developed by Le et al. who developed a platform utilizing gold nanoparticles that allowed for the visual detection of as little as 3E8 viral particles.¹³⁵ The gold nanoparticles were assembled with RNA aptamers that allowed for specific affinity with different strains of human influenza. Aptamers were selected in place of targeting mAbs due to cost effectiveness, as they are 1/1,000th the price per molecule. In the presence of viral contaminants, the functionalized nanoparticles form a gold nanoshell (AuNS) around the virus. This increase in mass allows for the sedimentation of viral contaminants, which can be facilitated with a portable mini-centrifuge. After 6–10 min of centrifugation at 2000 × g, visual sedimentation of nanoparticle-coated virus was reported within the range of the typical viral load in 1mL of human respiratory specimens.

While there are tests being developed to detect flaviviruses¹³⁶ there have been problems with differentiating between the various flaviviruses because of their structural similarities. Irene Bosch et al.¹³⁹ however, recently developed a dipstick type detection method to not only detect, but also differentiate between zika and dengue in an assay that take about 20 minutes.

Another unique POC diagnostic tool being developed uses not visual detection methods, but olfactory. This study utilized AuNPs and fragrance substrate molecules to detect *E. coli* by emission of a smell. Levels as low as 1E2 CFU/mL were able to be detected in about 15 min.¹⁴⁰

Discussion and Conclusion

As the need for rapid and accurate POC diagnostic tools continues to become more apparent, many platforms are being developed utilizing various methods and modalities. While many demonstrate impressive capabilities to detect pathogens or biomarkers in controlled lab environment, it is crucial to consider the characteristics required for realistic implementation throughout the entire development process. Each modality has its own pros and cons, but with careful planning, they all have the potential to facilitate successful POC diagnosis.

POC platforms utilizing optical modalities have a great deal of potential for customization due to the large numbers of fluorescent molecules available. This modality has been used in

many of the platforms discussed throughout this review, however it also faces some limitations, such as the sample preparation required to eliminate background noise from the intrinsic fluorescence properties many molecules have. The goal of POC diagnostic tools is to use raw samples such as blood, serum or urine with minimal to no preparation, so fluorescence-based platforms are often not ideal in this aspect. Additionally, the benchtop technologies required are costly and require trained personnel, further limiting its application in resource-limited settings where equipment is not easy to acquire. The ultimate goal of POC diagnostic technologies is to allow untrained personnel to easily utilize it in a portable manner.

Electrochemical POC diagnostic technology development has the most potential for miniaturization and portability, but its development alone can take a long time and be very costly. A large number of studies have developed potential prototypes that are portable and accurate, but these technologies still have a way to go before they are evaluated for effectiveness in the field. The glucometer is a good example of the potential for electrochemical diagnostic platforms, and it will not be surprising to see similar platforms reach the frontlines of POC detection in the near future.

The utilization of the magnetic properties of some nanoparticles allows for many of the downfalls of fluorescence detection methods to be overcome because this method can be utilized in opaque and non-processed solutions. Furthermore, the ability of magnetic nanoparticles to be manipulated by a magnetic field allows for a great deal of customization in development of various diagnostic tools. However, the current lack of portability and cost of the required machinery limit the utilization of many of these platforms as POC diagnostic tools. These hurdles will have to be overcome before they reach their full potential.

The colorimetric and lateral flow tests have had the most success in today's POC market as can be seen with HIV POC diagnosis and pregnancy tests. Several studies are in the process of developing similar platforms for other infectious diseases, and aim to be equally as rapid, accurate, portable and simple to use. Although lateral flow assays are purely qualitative, they seem to be an attractive option for many developing POC tests due to ease of use and little equipment requirements.

Overall, each modality has the potential for becoming an effective POC diagnostic tool but require further optimization and clinical testing before they reach their full potential. A summary of the pros and cons of each platform discussed within this review can be found in Tables 1–4. Many POC tests that have recently been implemented in clinical settings are colorimetric-based diagnostic technologies such as dipsticks and lateral flow assays. Currently there are POC colorimetric platforms being utilized that allow for the detection of HIV, malaria, leptospirosis, typhoid fever, human African trypanosomiasis, and visceral leishmaniasis. Paper based assays such as many lateral flow assays seem to be an attractive platform because no lab, power source, or sophisticated equipment is required.^{2,19–22,141} In addition to the success of these simpler assays, the increasingly rapid advancement of technology promises to offer new solutions to old problems, seen already with the increasing number of phone-based platforms in development. While there are many innovative platforms of all kinds currently in development, it remains of utmost importance to consider

the qualities needed for realistic implementation of these POC platforms at each stage in development. A focus on such qualities as timeliness, affordability, specificity, sensitivity, simplicity and portability will increase the rate at which these novel technologies leave the lab and find their place in the real world.

ACKNOWLEDGMENT

This project was supported by the National Institute of Health (NIH: 1 R03 AI132832-01) and Kansas INBRE grants (K-INBRE P20 GM103418), all to SS.

Abbreviations

POC	point-of-care
WHO	World Health Organization
ASSURED	Affordable, Sensitive, Specific, User-Friendly, Robust and rapid, Equipment free, Deliverable
PCR	polymerase chain reaction
ELISA	enzyme-linked immunosorbent assay
TB	tuberculosis
LOD	level of detection
FP	fluorescence polarization
QDs	Quantum Dots
mAbs	monoclonal antibodies
SPR	surface plasmon resonance
AuNPs	gold nanoparticles
FET	field effect transistor
DPV	differential pulse voltammetry
LAMP	loop mediated isothermal amplification
MEQ-LAMP	microfluidic electrochemical quantitative LAMP
SA	streptavidin
SPCE	screen-printed carbon electrode
MNPs	magnetic nanoparticles
T2	spin-spin relaxation time
MRnS	magnetic relaxation nanosensors

MFnS	magneto-fluorescent nanosensors
MMPs	magnetic microparticles
LFA	lateral flow assay
DRELFA	dual recognition element lateral flow assay

REFERENCES

- (1). Peeling RW; Mabey D Point-of-care tests for diagnosing infections in the developing world. *Clin. Microbiol. Infect* 2010, 16 (8), 1062–1069 DOI: 10.1111/j.1469-0691.2010.03279.x. [PubMed: 20670288]
- (2). Pai NP; Vadnais C; Denkinger C; Engel N; Pai M Point-of-Care Testing for Infectious Diseases: Diversity, Complexity, and Barriers in Low- And Middle-Income Countries. *PLoS Med* 2012, 9 (9) DOI: 10.1371/journal.pmed.1001306.
- (3). St John A; Price CP Existing and Emerging Technologies for Point-of-Care Testing. *Clin. Biochem. Rev* 2014, 35 (3), 155–167. [PubMed: 25336761]
- (4). Ly Sin M; Mach KE; Wong PK; Liao JC Advances and challenges in biosensor-based diagnosis of infectious diseases. *Expert Rev. Mol. Diagn* 2014, 1–20 DOI: 10.1586/14737159.2014.888313.
- (5). Franca RF; da Silva CC; De Paula SO Recent advances in molecular medicine techniques for the diagnosis, prevention, and control of infectious diseases. *Eur J Clin Microbiol Infect Dis* 2013 DOI: 10.1007/s10096-013-1813-0.
- (6). Fauci AS; Morens DM The Perpetual Challenge of Infectious Diseases. *N. Engl. J. Med* 2012, 366 (5), 454–461 DOI: 10.1056/NEJMr1108296. [PubMed: 22296079]
- (7). Yager P; Domingo GJ; Gerdes J Point-of-Care Diagnostics for Global Health. *Annu. Rev. Biomed. Eng* 2008, 10 (1), 107–144 DOI: 10.1146/annurev.bioeng.10.061807.160524. [PubMed: 18358075]
- (8). Qasim M; Lim D-J; Park H; Na D Nanotechnology for Diagnosis and Treatment of Infectious Diseases. *J. Nanosci. Nanotechnol* 2014, 14 (10), 7374–7387 DOI: 10.1166/jnn.2014.9578. [PubMed: 25942798]
- (9). Morens DM; Folkers GK; Fauci AS The challenge of emerging and re-emerging infectious diseases. *Nature* 2004, 430, 243–249 DOI: 10.1038/nature02759.
- (10). Morens DM; Folkers GK; Fauci AS The challenge of emerging and re-emerging infectious diseases. *Nature* 2010, 463 (7277), 122–122 DOI: 10.1038/nature08554.
- (11). Millet JP; Moreno A; Fina L; Del Baño L; Orcau A; De Olalla PG; Caylà JA Factors that influence current tuberculosis epidemiology. *European Spine Journal* 2013.
- (12). Vidic J; Manzano M; Chang C-M; Jaffrezic-Renault N Advanced biosensors for detection of pathogens related to livestock and poultry. *Vet. Res* 2018, 48 (1), 11 DOI: 10.1186/s13567-017-0418-5.
- (13). Sosnik A; Amiji M Nanotechnology solutions for infectious diseases in developing nations. *Adv. Drug Deliv. Rev* 2010, 62 (4–5), 375–377 DOI: 10.1016/j.addr.2009.11.010. [PubMed: 19913580]
- (14). Hartman LJ; Coyne SR; Norwood DA Development of a novel internal positive control for Taqman based assays. *Mol Cell Probes* 2005, 19 (1), 51–59 DOI: 10.1016/j.mcp.2004.07.006. [PubMed: 15652220]
- (15). Tighe PJ; Ryder RR; Todd I; Fairclough LC ELISA in the multiplex era: Potentials and pitfalls. *Proteomics - Clinical Applications* 2015, pp 406–422. [PubMed: 25644123]
- (16). Hauck TS; Giri S; Gao Y; Chan WCW Nanotechnology diagnostics for infectious diseases prevalent in developing countries. *Advanced Drug Delivery Reviews* 2010, pp 438–448. [PubMed: 19931580]
- (17). Bissonnette L; Bergeron MG Infectious disease management through point-of-care personalized medicine molecular diagnostic technologies. *J. Pers. Med* 2012, 2 (2), 50–70 DOI: 10.3390/jpm2020050. [PubMed: 25562799]

- (18). Drain PK; Hyle EP; Noubary F; Freedberg KA; Wilson D; Bishai W; Rodriguez W; Bassett IV Evaluating Diagnostic Point-of-Care Tests in Resource-Limited Settings 2015, 14 (3), 239–249 DOI: 10.1016/S1473-3099(13)70250-0.Evaluating.
- (19). Schito M; Peter TF; Cavanaugh S; Piatek AS; Young GJ; Alexander H; Coggin W; Domingo GJ; Ellenberger D; Ermantraut E; Jani I V; Katamba, A.; Palamounain, K. M.; Essajee, S.; Dowdy, D. W. Opportunities and challenges for cost-efficient implementation of new point-of-care diagnostics for HIV and tuberculosis. *J. Infect. Dis* 2012, 205 (SUPPL. 2), 169–180 DOI: 10.1093/infdis/jis044. [PubMed: 22158681]
- (20). DiMaio MA; Pereira IT; George TI; Banaei N Performance of BinaxNOW for diagnosis of malaria in a U.S. Hospital. *J. Clin. Microbiol* 2012, 50 (9), 2877–2880 DOI: 10.1128/JCM.01013-12. [PubMed: 22718936]
- (21). Delaney KP; Branson BM; Uniyal A; Phillips S; Candal D; Owen SM; Kerndt PR Evaluation of the performance characteristics of 6 rapid HIV antibody tests. *Clin. Infect. Dis* 2011, 52 (2), 257–263 DOI: 10.1093/cid/ciq068. [PubMed: 21288853]
- (22). Wilson ML Malaria rapid diagnostic tests. *Clin. Infect. Dis* 2012, 54 (11), 1637–1641 DOI: 10.1093/cid/cis228. [PubMed: 22550113]
- (23). Shin DJ; Athamanolap P; Chen L; Hardick J; Lewis M; Hsieh YH; Rothman RE; Gaydos CA; Wang TH Mobile nucleic acid amplification testing (mobiNAAT) for Chlamydia trachomatis screening in hospital emergency department settings. *Sci. Rep* 2017, 7 (1), 1–10 DOI: 10.1038/s41598-017-04781-8. [PubMed: 28127051]
- (24). Abu-Salah KM; Zourob MM; Mouffouk F; Alrokayan SA; Alaamery MA; Ansari AA DNA-based nanobiosensors as an emerging platform for detection of disease. *Sensors (Switzerland)* 2015, 15 (6), 14539–14568 DOI: 10.3390/s150614539.
- (25). Andreotti PE; Ludwig GV; Peruski AH; Tuite JJ; Morse SS; Peruski LF Immunoassay of infectious agents. *Biotechniques* 2003, 35 (4), 850–859. [PubMed: 14579751]
- (26). D’Orazio P Biosensors in clinical chemistry. *Clin. Chim. Acta* 2003, 334 (1–2), 41–69 DOI: 10.1016/S0009-8981(03)00241-9. [PubMed: 12867275]
- (27). Banala S; Arts R; Aper SJA; Merckx M No washing, less waiting: engineering biomolecular reporters for single-step antibody detection in solution. *Org. Biomol. Chem* 2013, 11 (44), 7642 DOI: 10.1039/c3ob41315b. [PubMed: 24091607]
- (28). Xu X; Akay A; Wei H; Wang S; Pingguan-Murphy B; Erlandsson BE; Li X; Lee W; Hu J; Wang L; Xu F Advances in Smartphone-Based Point-of-Care Diagnostics. *Proc. IEEE* 2015, 103 (2), 236–247 DOI: 10.1109/JPROC.2014.2378776.
- (29). Nasir MS; Jolley ME Fluorescence polarization: an analytical tool for immunoassay and drug discovery. *Comb. Chem. High Throughput Screen* 1999, 2 (4), 177–190. [PubMed: 10469879]
- (30). Park KS; Charles RC; Ryan ET; Weissleder R; Lee H Fluorescence polarization-based nucleic acid testing for rapid and cost-effective diagnosis of infectious disease. *Chemistry (Easton)* 2015, 21 (46), 16359–16363.
- (31). Wei AP; Herron JN Use of Synthetic Peptides as Tracer Antigens in Fluorescence Polarization Immunoassays of High Molecular Weight Analytes. *Anal. Chem* 1993, 65 (23), 3372–3377 DOI: 10.1021/ac00071a007. [PubMed: 8297026]
- (32). Wang Z-H; Zhang S-X; Shen J-Z; Eremin SA Development of fluorescence polarization immunoassay for determination of pesticides and veterinary drugs. *Guang Pu Xue Yu Guang Pu Fen Xi/Spectroscopy Spectr. Anal* 2007, 27 (11).
- (33). Zhang J; Tian J; He Y; Chen S; Jiang Y; Zhao Y; Zhao S Protein-binding aptamer assisted signal amplification for the detection of influenza A (H1N1) DNA sequences based on quantum dot fluorescence polarization analysis. *Analyst* 2013, 138 (17), 4722 DOI: 10.1039/c3an00830d. [PubMed: 23826611]
- (34). Walker GT; Nadeau JG; Linn CP; Devlin RF; Dandliker WB Strand displacement amplification (SDA) and transient-state fluorescence polarization detection of Mycobacterium tuberculosis DNA. *Clin. Chem* 1996, 42 (1), 9–13. [PubMed: 8565240]
- (35). Qin D; He X; Wang K; Zhao XJ; Tan W; Chen J Fluorescent nanoparticle-based indirect immunofluorescence microscopy for detection of Mycobacterium tuberculosis. *J. Biomed. Biotechnol* 2007, 2007 (7), 89364 DOI: 10.1155/2007/89364. [PubMed: 18273415]

- (36). Walker GT; Linn CP Detection of Mycobacterium tuberculosis DNA with thermophilic strand displacement amplification and fluorescence polarization. Clin. Chem 1996, 42 (10), 1604–1608. [PubMed: 8855142]
- (37). Lucero NE; Escobar GI; Ayala SM; Paulo PS; Nielsen KH Fluorescence polarization assay for diagnosis of human brucellosis. J. Med. Microbiol 2003, 52 (10), 883–887. [PubMed: 12972582]
- (38). Chi X; Huang D; Zhao Z; Zhou Z; Yin Z; Gao J Nanoprobes for in vitro diagnostics of cancer and infectious diseases. Biomaterials 2012, 33 (1), 189–206 DOI: 10.1016/j.biomaterials.2011.09.032. [PubMed: 21959007]
- (39). Qasim Muhammad; Lim D-J; Park H; Na D Nanotechnology for Diagnosis and Treatment of Infectious Diseases. J. Nanosci. Nanotechnol 2014, 14, 7374–7387 DOI: 10.1166/jnn.2014.9578. [PubMed: 25942798]
- (40). Myers FB; Lee LP Innovations in optical microfluidic technologies for point-of-care diagnostics. Lab Chip 2008, 8 (12), 2015 DOI: 10.1039/b812343h. [PubMed: 19023464]
- (41). Takemura K; Adegoke O; Takahashi N; Kato T; Li TC; Kitamoto N; Tanaka T; Suzuki T; Park EY Versatility of a localized surface plasmon resonance-based gold nanoparticle-alloyed quantum dot nanobiosensor for immunofluorescence detection of viruses. Biosens. Bioelectron 2017, 89, 998–1005 DOI: 10.1016/j.bios.2016.10.045. [PubMed: 27825520]
- (42). Ming K; Kim J; Biondi MJ; Syed A; Chen K; Lam A; Ostrowski M; Rebbapragada A; Feld JJ; Chan WCW Integrated quantum dot barcode smartphone optical device for wireless multiplexed diagnosis of infected patients. ACS Nano 2015, 9 (3), 3060–3074 DOI: 10.1021/nn5072792. [PubMed: 25661584]
- (43). Xiong LH; Cui R; Zhang ZL; Yu X; Xie Z; Shi YB; Pang DW Uniform fluorescent nanobioprobes for pathogen detection. ACS Nano 2014, 8 (5), 5116–5124 DOI: 10.1021/nn501174g. [PubMed: 24779675]
- (44). Hsieh K; Ferguson BS; Eisenstein M; Plaxco KW; Soh HT Integrated electrochemical microsystems for genetic detection of pathogens at the point of care. Acc. Chem. Res 2015, 48 (4), 911–920 DOI: 10.1021/ar500456w. [PubMed: 25785632]
- (45). Su W; Gao X; Jiang L; Qin J Microfluidic platform towards point-of-care diagnostics in infectious diseases. Journal of Chromatography A 2015, pp 13–26.
- (46). Zhang RQ; Liu SL; Zhao W; Zhang WP; Yu X; Li Y; Li AJ; Pang DW; Zhang ZL A simple point-of-care microfluidic immunomagnetic fluorescence assay for pathogens. Anal. Chem 2013, 85 (5), 2645–2651 DOI: 10.1021/ac302903p. [PubMed: 23391352]
- (47). Lagelly ET; Scherer JR; Blazej RG; Toriello NM; Diep BA; Ramchandani M; Sensabaugh GF; Riley LW; Mathies RA Integrated portable genetic analysis microsystem for pathogen/infectious disease detection. Anal. Chem 2004, 76 (11), 3162–3170 DOI: 10.1021/ac035310p. [PubMed: 15167797]
- (48). Sugino H; Ozaki K; Shirasaki Y; Arakawa T; Shoji S; Funatsu T On-chip microfluidic sorting with fluorescence spectrum detection and multiway separation. Lab Chip 2009, 9 (9), 1254–1260 DOI: 10.1039/B815765K. [PubMed: 19370245]
- (49). Kalgala GV; Huskins RJ; Preiksaitis J; Pang XL; Pilarski LM; Backhouse CJ Automated screening using microfluidic chip-based PCR and product detection to assess risk of BK virus-associated nephropathy in renal transplant recipients. Electrophoresis 2006, 27 (19), 3753–3763 DOI: 10.1002/elps.200600061. [PubMed: 16960845]
- (50). Iswady E; Tsai TC; Cheng IF; Ho TC; Chuen Perng G; Chang HC A bead-based immunofluorescence-assay on a microfluidic dielectrophoresis platform for rapid dengue virus detection. Biosens. Bioelectron 2017, 97 (June), 400 DOI: 10.1016/j.bios.2017.05.038. [PubMed: 28579306]
- (51). Huang FC; Liao CS; Lee G Bin. An integrated microfluidic chip for DNA/RNA amplification, electrophoresis separation and on-line optical detection. Electrophoresis 2006, 27 (16), 3297–3305 DOI: 10.1002/elps.200600458. [PubMed: 16865670]
- (52). Huang S; Li C; Lin B; Qin J Microvalve and micropump controlled shuttle flow microfluidic device for rapid DNA hybridization. Lab Chip 2010, 10 (21), 2925 DOI: 10.1039/c005227b. [PubMed: 20830429]

- (53). Easley CJ; Karlinsey JM; Landers JP On-chip pressure injection for integration of infrared-mediated DNA amplification with electrophoretic separation. *Lab Chip* 2006, 6 (5), 601–610 DOI: 10.1039/b600039h. [PubMed: 16652175]
- (54). Soler M; Belushkin A; Cavallini A; Kebbi-Beghdadi C; Greub G; Altug H Multiplexed nanoplasmonic biosensor for one-step simultaneous detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* in urine. *Biosens. Bioelectron* 2017, 94 (January), 560–567 DOI: 10.1016/j.bios.2017.03.047. [PubMed: 28364702]
- (55). Banerjee T; Sulthana S; Shelby T; Heckert B; Jewell J; Woody K; Karimnia V; McAfee J; Santra S Multiparametric Magneto-fluorescent Nanosensors for the Ultrasensitive Detection of *Escherichia coli* O157:H7. *ACS Infect. Dis* 2016, 2 (10), 667–673 DOI: 10.1021/acsinfecdis.6b00108. [PubMed: 27737552]
- (56). Gharatape A; Salehi R Recent progress in theranostic applications of hybrid gold nanoparticles. *European Journal of Medicinal Chemistry* 2017, pp 221–233.
- (57). Kim J; Jang M; Lee KG; Lee KS; Lee SJ; Ro KW; Kang IS; Jeong B. Do; Park TJ; Kim HJ; Lee J Plastic-Chip-Based Magnetophoretic Immunoassay for Point-of-Care Diagnosis of Tuberculosis. *ACS Appl. Mater. Interfaces* 2016, 8 (36), 23489–23497 DOI: 10.1021/acsami.6b06924. [PubMed: 27548010]
- (58). Park TJ; Lee SJ; Kim DK; Heo NS; Park JY; Lee SY Development of label-free optical diagnosis for sensitive detection of influenza virus with genetically engineered fusion protein. *Talanta* 2012, 89, 246–252 DOI: 10.1016/j.talanta.2011.12.021. [PubMed: 22284487]
- (59). Yu M; Wang H; Fu F; Li L; Li G; Song Y; Swihart MT; Song E Dual-Recognition Förster Resonance Energy Transfer Based Platform for One-Step Sensitive Detection of Pathogenic Bacteria Using Fluorescent Vancomycin-Gold Nanoclusters and Aptamer-Gold Nanoparticles. *Anal. Chem* 2017, 89 (7), 4085–4090 DOI: 10.1021/acs.analchem.6b04958. [PubMed: 28287715]
- (60). Iswardy E; Tsai TC; Cheng IF; Ho TC; Perng GC; Chang HC A bead-based immunofluorescence-assay on a microfluidic dielectrophoresis platform for rapid dengue virus detection. *Biosens. Bioelectron* 2017, 95 (1), 174–180 DOI: 10.1016/j.bios.2017.04.011. [PubMed: 28453962]
- (61). Park TJ; Lee SJ; Kim DK; Heo NS; Park JY; Lee SY Development of label-free optical diagnosis for sensitive detection of influenza virus with genetically engineered fusion protein. *Talanta* 2012, 89, 246–252 DOI: 10.1016/j.talanta.2011.12.021. [PubMed: 22284487]
- (62). Ahmed A; Rushworth JV; Hirst NA; Millner PA Biosensors for whole-cell bacterial detection. *Clin. Microbiol. Rev* 2014, 27 (3), 631–646 DOI: 10.1128/CMR.00120-13. [PubMed: 24982325]
- (63). Adkins J; Boehle K; Henry C Electrochemical paper-based microfluidic devices. *Electrophoresis* 2015, pp 1811–1824. [PubMed: 25820492]
- (64). Ng BYC; Xiao W; West NP; Wee EJJ; Wang Y; Trau M Rapid, Single-Cell Electrochemical Detection of *Mycobacterium tuberculosis* Using Colloidal Gold Nanoparticles. *Anal. Chem* 2015, 87 (20), 10613–10618 DOI: 10.1021/acs.analchem.5b03121. [PubMed: 26382883]
- (65). Sepunaru L; Plowman BJ; Sokolov SV; Young NP; Compton RG Rapid electrochemical detection of single influenza viruses tagged with silver nanoparticles. *Chem. Sci* 2016, 7 (6), 3892–3899 DOI: 10.1039/C6SC00412A. [PubMed: 30155033]
- (66). Hideshima S; Hinou H; Ebihara D; Sato R; Kuroiwa S; Nakanishi T; Nishimura SI; Osaka T Attomolar detection of influenza A virus hemagglutinin human H1 and avian H5 using glycan-blotted field effect transistor biosensor. *Anal. Chem* 2013, 85 (12), 5641–5644 DOI: 10.1021/ac401085c. [PubMed: 23675869]
- (67). Andresen D; Balkenhohl T Biosensing for the 21st Century; 2013; Vol. 53.
- (68). Patolsky F; Zheng G; Hayden O; Lakadamyali M; Zhuang X; Lieber CM Electrical detection of single viruses. *Proc. Natl. Acad. Sci. U. S. A* 2004, 101 (39), 14017–14022 DOI: 10.1073/pnas.0406159101. [PubMed: 15365183]
- (69). Park J; Hiep H; Woubit A; Kim M Applications of Field-Effect Transistor (FET) -Type Biosensors. *Appl. Sci. Conver. Technol* 2014, 23 (2), 61–71.

- (70). Tarasov A; Gray DW; Tsai MY; Shields N; Montrose A; Creedon N; Lovera P; O’Riordan A; Mooney MH; Vogel EM A potentiometric biosensor for rapid on-site disease diagnostics. *Biosens. Bioelectron* 2016, 79, 669–678 DOI: 10.1016/j.bios.2015.12.086. [PubMed: 26765531]
- (71). Afsahi S; Lerner MB; Goldstein JM; Lee J; Tang X; Bagarozzi DA; Pan D; Locascio L; Walker A; Barron F; Goldsmith BR Novel graphene-based biosensor for early detection of Zika virus infection. *Biosens. Bioelectron* 2018, 100 (June 2017), 85–88 DOI: 10.1016/j.bios.2017.08.051. [PubMed: 28865242]
- (72). Sassa F; Morimoto K; Satoh W; Suzuki H Electrochemical techniques for microfluidic applications. *Electrophoresis* 2008, 29 (9), 1787–1800 DOI: 10.1002/elps.200700581. [PubMed: 18384068]
- (73). Kelley SO; Mirkin CA; Walt DR; Ismagilov RF; Toner M; Sargent EH Advancing the speed, sensitivity and accuracy of biomolecular detection using multi-length-scale engineering. *Nat. Nanotechnol* 2014, 9 (12), 969–980 DOI: 10.1038/nnano.2014.261. [PubMed: 25466541]
- (74). Lillehoj PB; Kaplan CW; He J; Shi W; Ho C-M Rapid, Electrical Impedance Detection of Bacterial Pathogens Using Immobilized Antimicrobial Peptides. *J. Lab. Autom* 2013, 19 (1), 42–49 DOI: 10.1177/2211068213495207. [PubMed: 23850865]
- (75). Krejcová L; Nejdil L; Rodrigo MAM; Zurek M; Matousek M; Hynek D; Zitka O; Kopel P; Adam V; Kizek R 3D printed chip for electrochemical detection of influenza virus labeled with CdS quantum dots. *Biosens. Bioelectron* 2014, 54, 421–427 DOI: 10.1016/j.bios.2013.10.031. [PubMed: 24296063]
- (76). Singh R; Hong S; Jang J Label-free Detection of Influenza Viruses using a Reduced Graphene Oxide-based Electrochemical Immunosensor Integrated with a Microfluidic Platform. *Sci. Rep* 2017, 7 DOI: 10.1038/srep42771. [PubMed: 28127057]
- (77). Bunyakul N; Promptmas C; Baeumner AJ Microfluidic biosensor for cholera toxin detection in fecal samples. *Anal. Bioanal. Chem* 2015, 407 (3), 727–736 DOI: 10.1007/s00216-014-7947-9. [PubMed: 24958345]
- (78). Luo J; Fang X; Ye D; Li H; Chen H; Zhang S; Kong J A real-time microfluidic multiplex electrochemical loop-mediated isothermal amplification chip for differentiating bacteria. *Biosens. Bioelectron* 2014, 60, 84–91 DOI: 10.1016/j.bios.2014.03.073. [PubMed: 24787122]
- (79). Hsieh K; Patterson AS; Ferguson BS; Plaxco KW; Soh HT Rapid, sensitive, and quantitative detection of pathogenic DNA at the point of care through microfluidic electrochemical quantitative loop-mediated isothermal amplification. *Angew. Chemie - Int. Ed* 2012, 51 (20), 4896–4900 DOI: 10.1002/anie.201109115.
- (80). Cortina ME; Melli LJ; Roberti M; Mass M; Longinotti G; Tropea S; Lloret P; Serantes DAR; Salomón F; Lloret M; Caillava AJ; Restuccia S; Altchek J; Buscaglia CA; Malatto L; Ugalde JE; Fraigi L; Moína C; Ybarra G; Ciocchini AE; Comerci DJ Electrochemical magnetic microbeads-based biosensor for point-of-care serodiagnosis of infectious diseases. *Biosens. Bioelectron* 2016, 80, 24–33 DOI: 10.1016/j.bios.2016.01.021. [PubMed: 26802749]
- (81). Damhorst GL; Murtagh M; Rodriguez WR; Bashir R Microfluidics and Nanotechnology for Detection of Global Infectious Diseases. *Proceedings of the IEEE* 2015, pp 150–160.
- (82). Bai L; Chen Y; Bai Y; Chen Y; Zhou J; Huang A Fullerene-doped polyaniline as new redox nanoprobe and catalyst in electrochemical aptasensor for ultrasensitive detection of Mycobacterium tuberculosis MPT64 antigen in human serum. *Biomaterials* 2017, 133, 11–19 DOI: 10.1016/j.biomaterials.2017.04.010. [PubMed: 28414975]
- (83). Fang Y-S; Chen S-Y; Huang X-J; Wang L-S; Wang H-Y; Wang J-F Simple approach for ultrasensitive electrochemical immunoassay of Clostridium difficile toxin B detection. *Biosens. Bioelectron* 2014, 53, 238–244 DOI: 10.1016/j.bios.2013.09.063. [PubMed: 24141113]
- (84). Cecchetto J; Fernandes FCB; Lopes R; Bueno PR The capacitive sensing of NS1 Flavivirus biomarker. *Biosens. Bioelectron* 2017, 87, 949–956 DOI: 10.1016/j.bios.2016.08.097. [PubMed: 27665517]
- (85). Hushegyi A; Pihíková D; Bertok T; Adam V; Kizek R; Tkac J Ultrasensitive detection of influenza viruses with a glycan-based impedimetric biosensor. *Biosens. Bioelectron* 2016, 79, 644–649 DOI: 10.1016/j.bios.2015.12.102. [PubMed: 26765527]

- (86). Shafiee H; Jahangir M; Inci F; Wang S; Willenbrecht RBM; Giguel FF; Tsibris AMN; Kuritzkes DR; Demirci U Acute on-chip HIV detection through label-free electrical sensing of viral nano-lysate. *Small* 2013, 9 (15), 2553–2563 DOI: 10.1002/sml.201202195. [PubMed: 23447456]
- (87). Guo X; Kulkarni A; Doepke A; Halsall HB; Iyer S; Heineman WR Carbohydrate-based label-free detection of escherichia coli ORN 178 using electrochemical impedance spectroscopy. *Anal. Chem* 2012, 84 (1), 241–246 DOI: 10.1021/ac202419u. [PubMed: 22035288]
- (88). Diouani MF; Ouerghi O; Refai A; Belgacem K; Tlili C; Laouini D; Essafi M Detection of ESAT-6 by a label free miniature immuno-electrochemical biosensor as a diagnostic tool for tuberculosis. *Mater. Sci. Eng. C* 2017, 74, 465–470 DOI: 10.1016/j.msec.2016.12.051.
- (89). Torati SR; Reddy V; Yoon SS; Kim CG Electrochemical biosensor for Mycobacterium tuberculosis DNA detection based on gold nanotubes array electrode platform. *Biosens. Bioelectron* 2016, 78, 483–488 DOI: 10.1016/j.bios.2015.11.098. [PubMed: 26657592]
- (90). Li Y; Xiong Y; Fang L; Jiang L; Huang H; Deng J; Liang W; Zheng J An Electrochemical Strategy using Multifunctional Nanoconjugates for Efficient Simultaneous Detection of Escherichia coli O157: H7 and Vibrio cholerae O1. *Theranostics* 2017, 7 (4), 935–944 DOI: 10.7150/thno.17544. [PubMed: 28382165]
- (91). Laczka O; Ferraz RM; Ferrer-Miralles N; Villaverde A; Muñoz FX; Campo FJ del. Fast electrochemical detection of anti-HIV antibodies: Coupling allosteric enzymes and disk microelectrode arrays. *Anal. Chim. Acta* 2009, 641 (1–2), 1–6 DOI: 10.1016/j.aca.2009.03.008. [PubMed: 19393360]
- (92). Hu C; Kalsi S; Zeimpekis I; Sun K; Ashburn P; Turner C; Sutton JM; Morgan H Ultra-fast electronic detection of antimicrobial resistance genes using isothermal amplification and Thin Film Transistor sensors. *Biosens. Bioelectron* 2017, 96 (January), 281–287 DOI: 10.1016/j.bios.2017.05.016. [PubMed: 28505562]
- (93). Luo J; Fang X; Ye D; Li H; Chen H; Zhang S; Kong J A real-time microfluidic multiplex electrochemical loop-mediated isothermal amplification chip for differentiating bacteria. *Biosens. Bioelectron* 2014, 60, 84–91 DOI: 10.1016/j.bios.2014.03.073. [PubMed: 24787122]
- (94). Lee KH; Zeng H Aptamer-Based ELISA Assay for Highly Specific and Sensitive Detection of Zika NS1 Protein. *Anal. Chem* 2017, 89 (23), 12743–12748 DOI: 10.1021/acs.analchem.7b02862. [PubMed: 29120623]
- (95). Diouani MF; Ouerghi O; Refai A; Belgacem K; Tlili C; Laouini D; Essafi M Detection of ESAT-6 by a label free miniature immuno-electrochemical biosensor as a diagnostic tool for tuberculosis. *Mater. Sci. Eng. C* 2017, 74, 465–470 DOI: 10.1016/j.msec.2016.12.051.
- (96). Koh I; Josephson L Magnetic Nanoparticle Sensors. *Sensors* 2009, 9 (10), 8130–8145 DOI: 10.3390/s91008130. [PubMed: 22408498]
- (97). Perez JM; Josephson L; Weissleder R Use of magnetic nanoparticles as nanosensors to probe for molecular interactions. *ChemBioChem* 2004, 5 (3), 261–264. [PubMed: 14997516]
- (98). Josephson L; Manuel Perez J; Weissleder R Magnetic nanosensors for the detection of oligonucleotide sequences. *Angew. Chemie - Int. Ed* 2001, 40 (17), 3204–3206 DOI: 10.1002/1521-3773(20010903)40:17<3204::AID-ANIE3204>3.0.CO;2-H.
- (99). Agiotis L; Theodorakos I; Samothrakitis S; Papazoglou S; Zergioti I; Raptis YS Magnetic manipulation of superparamagnetic nanoparticles in a microfluidic system for drug delivery applications. *Journal of Magnetism and Magnetic Materials* 2016, pp 956–964.
- (100). Santiesteban OJ; Kaittanis C; Perez JM Assessment of molecular interactions through magnetic relaxation. *Angew. Chemie - Int. Ed* 2012, 51 (27), 6728–6732 DOI: 10.1002/anie.201202077.
- (101). Osterfeld SJ; Yu H; Gaster RS; Caramuta S; Xu L; Han S-J; Hall DA; Wilson RJ; Sun S; White RL; Davis RW; Pourmand N; Wang SX Multiplex protein assays based on real-time magnetic nanotag sensing. *Proc. Natl. Acad. Sci* 2008, 105 (52), 20637–20640 DOI: 10.1073/pnas.0810822105. [PubMed: 19074273]
- (102). Lin G; Makarov D; Schmidt OG Magnetic sensing platform technologies for biomedical applications. *Lab Chip* 2017, 17 (11), 1884–1912 DOI: 10.1039/C7LC00026J. [PubMed: 28485417]

- (103). Krishna VD; Wu K; Perez AM; Wang JP Giant magnetoresistance-based biosensor for detection of influenza A virus. *Front. Microbiol* 2016, 7 (MAR), 1–8 DOI: 10.3389/fmicb.2016.00400. [PubMed: 26834723]
- (104). Rowland CE; Brown CW; Delehanty JB; Medintz IL Nanomaterial-based sensors for the detection of biological threat agents. *Materials Today* 2016, pp 464–477.
- (105). Kearns H; Goodacre R; Jamieson L; Graham D; Faulds K SERS Detection of Multiple Anti-microbial Resistant Pathogens using Nanosensors. *Anal. Chem* 2017 DOI: 10.1021/acs.analchem.7b02653.
- (106). Shelby T; Banerjee T; Kallu J; Sulthana S; Zegar I; Santra S Novel magnetic relaxation nanosensors: an unparalleled “spin” on influenza diagnosis. *Nanoscale* 2016, 8 (47), 19605–19613 DOI: 10.1039/C6NR05889B. [PubMed: 27778002]
- (107). Santiesteban OJ; Kaittanis C; Perez JM Identification of toxin inhibitors using a magnetic nanosensor-based assay. *Small* 2014, 10 (6), 1202–1211 DOI: 10.1002/smll.201301824. [PubMed: 24339142]
- (108). Huang C-C; Zhou X; Hall DA Giant Magnetoresistive Biosensors for Time-Domain Magnetorelaxometry: A Theoretical Investigation and Progress Toward an Immunoassay. *Sci. Rep* 2017, 7, 45493 DOI: 10.1038/srep45493. [PubMed: 28374833]
- (109). Barroso TG; Martins RC; Fernandes E; Cardoso S; Rivas J; Freitas PP Detection of BCG bacteria using a magnetoresistive biosensor: a step towards a fully electronic platform for tuberculosis point-of-care detection. *Biosens. Bioelectron* 2017 DOI: 10.1016/j.bios.2017.09.004.
- (110). Tian B; Qiu Z; Ma J; Zardán Gómez de la Torre, T.; Johansson, C.; Svedlindh, P.; Strömberg, M. Attomolar Zika virus oligonucleotide detection based on loop-mediated isothermal amplification and AC susceptometry. *Biosens. Bioelectron* 2016, 86, 420–425 DOI: 10.1016/j.bios.2016.06.085. [PubMed: 27423039]
- (111). Bejhed RS; Zardán Gómez De La Torre T; Donolato M; Hansen MF; Svedlindh P; Strömberg M Turn-on optomagnetic bacterial DNA sequence detection using volume-amplified magnetic nanobeads. *Biosens. Bioelectron* 2015, 66, 405–411 DOI: 10.1016/j.bios.2014.11.048. [PubMed: 25483917]
- (112). Tian B; Bejhed RS; Svedlindh P; Stromberg M Blu-ray optomagnetic measurement based competitive immunoassay for Salmonella detection. *Biosens. Bioelectron* 2016, 77, 32–39 DOI: 10.1016/j.bios.2015.08.070. [PubMed: 26386328]
- (113). Lee H; Sun E; Ham D; Weissleder R Chip–NMR biosensor for detection and molecular analysis of cells. *Nat. Med* 2008, 14 (8), 869–874 DOI: 10.1038/nm.1711. [PubMed: 18607350]
- (114). Liong M; Hoang AN; Chung J; Gural N; Ford CB; Min C; Shah RR; Ahmad R; Fernandez-Suarez M; Fortune SM; Toner M; Lee H; Weissleder R Magnetic barcode assay for genetic detection of pathogens. *Nat. Commun* 2013, 4, 1752 DOI: 10.1038/ncomms2745. [PubMed: 23612293]
- (115). Aytur T; Foley J; Anwar M; Boser B; Harris E; Beatty PR A novel magnetic bead bioassay platform using a microchip-based sensor for infectious disease diagnosis. *J. Immunol. Methods* 2006, 314 (1–2), 21–29 DOI: 10.1016/j.jim.2006.05.006. [PubMed: 16842813]
- (116). Shelby T; Banerjee T; Kallu J; Sulthana S; Zegar I; Santra S Novel magnetic relaxation nanosensors: An unparalleled “spin” on influenza diagnosis. *Nanoscale* 2016, 8 (47), 19605–19613 DOI: 10.1039/c6nr05889b. [PubMed: 27778002]
- (117). Sharma S; Zapatero-Rodriguez J; Estrela P; O’Kennedy R Point-of-Care diagnostics in low resource settings: Present status and future role of microfluidics. *Biosensors* 2015, 5 (3), 577–601 DOI: 10.3390/bios5030577. [PubMed: 26287254]
- (118). Koczula KM; Gallotta A Lateral flow assays. *Essays Biochem* 2016, 60 (1), 111–120 DOI: 10.1042/EBC20150012. [PubMed: 27365041]
- (119). Shah M; Hanrahan C; Wang ZY; Dendukuri N; Lawn SD; Denkinger CM; Steingart KR Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults. *Cochrane Database Syst. Rev* 2016, 2016 (5) DOI: 10.1002/14651858.CD011420.pub2.
- (120). Hanifa Y; Fielding KL; Chihota VN; Adonis L; Charalambous S; Karstaedt A; McCarthy K; Nicol MP; Ndlovu NT; Sahid F; Churchyard GJ; Grant AD Diagnostic accuracy of lateral flow

urine LAM assay for TB screening of adults with advanced immunosuppression attending routine HIV care in South Africa. PLoS One 2016, 11 (6), 1–12 DOI: 10.1371/journal.pone.0156866.

- (121). World Health Organization. The use of lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis and screening of active tuberculosis in people living with HIV: policy 2015, 1–74 DOI: 978 92 4 150963 3.
- (122). Gonzalez JM; Francis B; Burda S; Hess K; Behera D; Gupta D; Agarwal AN; Verma I; Verma A; Myneedu VP; Niedbala S; Laal S Development of a POC Test for TB Based on Multiple Immunodominant Epitopes of *M. tuberculosis* Specific Cell-Wall Proteins. PLoS One 2014, 9 (9), 1–10 DOI: 10.1371/journal.pone.0106279.
- (123). Le TT; Chang P; Benton D; John W; Iqbal M; Edward A; Cass G Dual Recognition Element Lateral Flow Assay (DRELFA) - Towards Multiplex Strain Specific Influenza Virus Detection. Anal. Chem 2017, 89 (12), 6781–6786 DOI: 10.1021/acs.analchem.7b01149. [PubMed: 28558471]
- (124). Yeo S; Choi K; Cuc BT; Hong NN; Bao DT; Minh N Smartphone-Based Fluorescent Diagnostic System for Highly Pathogenic H5N1 Viruses. Theranostics 2016, 6 (2) DOI: 10.7150/thno.14023.
- (125). Wang Y; Li H; Wang Y; Zhang L; Xu J; Ye C Loop-mediated isothermal amplification label-based gold nanoparticles lateral flow biosensor for detection of *Enterococcus faecalis* and *Staphylococcus aureus*. Front. Microbiol 2017, 8 (FEB) DOI: 10.3389/fmicb.2017.00192.
- (126). Wang Y; Li H; Wang Y; Li H; Luo L; Xu J; Ye C Development of multiple cross displacement amplification label-based gold nanoparticles lateral flow biosensor for detection of *Listeria monocytogenes*. Int. J. Nanomedicine 2017, 12, 473–486 DOI: 10.2147/IJN.S123625. [PubMed: 28138243]
- (127). Wang Y; Wang Y; Xu J; Ye C Development of Multiple Cross Displacement Amplification Label-Based Gold Nanoparticles Lateral Flow Biosensor for Detection of *Shigella* spp. Front. Microbiol 2016, 7 (November), 1834 DOI: 10.3389/fmicb.2016.01834. [PubMed: 27917160]
- (128). Yen C-W; de Puig H; Tam JO; Gómez-Márquez J; Bosch I; Hamad-Schifferli K; Gehrke L Multicolored silver nanoparticles for multiplexed disease diagnostics: distinguishing dengue, yellow fever, and Ebola viruses. Lab Chip 2015, 15 (7), 1638–1641 DOI: 10.1039/C5LC00055F. [PubMed: 25672590]
- (129). Nurul Najian AB; Engku Nur Syafirah EAR; Ismail N; Mohamed M; Yean CY Development of multiplex loop mediated isothermal amplification (m-LAMP) label-based gold nanoparticles lateral flow dipstick biosensor for detection of pathogenic *Leptospira*. Anal. Chim. Acta 2016, 903, 142–148 DOI: 10.1016/j.aca.2015.11.015. [PubMed: 26709307]
- (130). Lin C; Zhang Y; Zhou X; Yao B; Fang Q Naked-eye detection of nucleic acids through rolling circle amplification and magnetic particle mediated aggregation. Biosens. Bioelectron 2013, 47, 515–519 DOI: 10.1016/j.bios.2013.03.056. [PubMed: 23643944]
- (131). Ding X; Wu W; Zhu Q; Zhang T; Jin W; Mu Y Mixed-Dye-Based Label-Free and Sensitive Dual Fluorescence for the Product Detection of Nucleic Acid Isothermal Multiple-Self-Matching-Initiated Amplification. Anal. Chem 2015, 87 (20), 10306–10314 DOI: 10.1021/acs.analchem.5b02112. [PubMed: 26383158]
- (132). Wang YF; Pang DW; Zhang ZL; Zheng HZ; Cao JP; Shen JT Visual gene diagnosis of HBV and HCV based on nanoparticle probe amplification and silver staining enhancement. J. Med. Virol 2003, 70 (2), 205–211 DOI: 10.1002/jmv.10379. [PubMed: 12696106]
- (133). Ng BYC; Wee EJH; West NP; Trau M Naked-Eye Colorimetric and Electrochemical Detection of *Mycobacterium tuberculosis*—toward Rapid Screening for Active Case Finding. ACS Sensors 2016, 1 (2), 173–178 DOI: 10.1021/acssensors.5b00171.
- (134). Baptista PV; Koziol-Montewka M; Paluch-Oles J; Doria G; Franco R Gold-nanoparticle-probe-based assay for rapid and direct detection of *Mycobacterium tuberculosis* DNA in clinical samples. Clinical Chemistry 2006, pp 1433–1434. [PubMed: 16798971]
- (135). Le TT; Adamiak B; Benton DJ; Johnson CJ; Sharma S; Fenton R; McCauley JW; Iqbal M; Cass AEG Aptamer-based biosensors for the rapid visual detection of flu viruses. Chem. Commun 2014, 50 (98), 15533–15536 DOI: 10.1039/C4CC07888H.

- (136). Yaren O; Alto BW; Gangodkar PV; Ranade SR; Patil KN; Bradley KM; Yang Z; Phadke N; Benner SA Point of sampling detection of Zika virus within a multiplexed kit capable of detecting dengue and chikungunya. *BMC Infect. Dis* 2017, 17 (1), 293 DOI: 10.1186/s12879-017-2382-0. [PubMed: 28427352]
- (137). Chen J; Alcaine SD; Jackson AA; Rotello VM; Nugen SR Development of Engineered Bacteriophages for Escherichia coli Detection and High-Throughput Antibiotic Resistance Determination. *ACS Sensors* 2017, 2 (4), 484–489 DOI: 10.1021/acssensors.7b00021. [PubMed: 28723178]
- (138). Driskell JD; Jones CA; Tompkins SM; Tripp RA One-step assay for detecting influenza virus using dynamic light scattering and gold nanoparticles. *Analyst* 2011, 136 (15), 3083 DOI: 10.1039/c1an15303j. [PubMed: 21666913]
- (139). Bosch I; De Puig H; Hiley M; Carré-Camps M; Perdomo-Celis F; Narváez CF; Salgado DM; Senthooor D; O'Grady M; Phillips E; Durbin A; Fandos D; Miyazaki H; Yen CW; Gélvez-Ramírez M; Warke RV; Ribeiro LS; Teixeira MM; Almeida RP; Muñoz-Medina JE; Ludert JE; Nogueira ML; Colombo TE; Terzian ACB; Bozza PT; Calheiros AS; Vieira YR; Barbosa-Lima G; Vizzoni A; Cerbino-Neto J; Bozza FA; Souza TML; Trugilho MRO; Filippis AMB; Sequeira PC; Marques ETA; Magalhaes T; Díaz FJ; Restrep BN; Marín K; Mattar S; Olson D; Asturias EJ; Lucera M; Singla M; Medigeshe GR; Bosch N; Tam J; Gómez-Márquez J; Clavet C; Villar L; Hamad-Schifferli K; Gehrke L Rapid antigen tests for dengue virus serotypes and Zika virus in patient serum. *Sci. Transl. Med* 2017, No. September DOI: 10.1126/scitranslmed.aan1589.
- (140). Duncan B; Le NDB; Alexander C; Gupta A; Yesilbag Tonga G; Yazdani M; Landis RF; Wang LS; Yan B; Burmaoglu S; Li X; Rotello VM Sensing by Smell: Nanoparticle-Enzyme Sensors for Rapid and Sensitive Detection of Bacteria with Olfactory Output. *ACS Nano* 2017, 11 (6), 5339–5343 DOI: 10.1021/acsnano.7b00822. [PubMed: 28423269]
- (141). Barbé B; Verdonck K; El-Safi S; Khanal B; Teav S; Lilo Kalo JR; Ravinetto R; Chappuis F; Boelaert M; Jacobs J Rapid Diagnostic Tests for Neglected Infectious Diseases: Case Study Highlights Need for Customer Awareness and Postmarket Surveillance. *PLoS Negl. Trop. Dis* 2016, 10 (11), 1–8 DOI: 10.1371/journal.pntd.0004655.

Figure 1:

A) representation of MEQ-LAMP chip used by Hsieh et al. for the detection of *Salmonella*⁴⁴ for infectious disease detection. B) The Methylene Blue molecule in this electrochemical setup allow for real-time detection of the LAMP reaction. Reprinted with permission from reference (79) Hsieh, K.; Patterson, A. S.; Ferguson, B. S.; Plaxco, K. W.; Soh, H. T. Rapid, sensitive, and quantitative detection of pathogenic DNA at the point of care through microfluidic electrochemical quantitative loop-mediated isothermal amplification. *Angew. Chemie - Int. Ed.* **2012**, *51* (20), 4896–4900. Copyright 2012, John Wiley and Sons.

Figure 2:

Sandwich type immunoassay based magnetoresistive sensors which can be utilized to detect various infectious diseases. (A) Antibody is fixed to a surface. (B) Analyte is washed over and allowed to bind to antibody. (C) Biotinylated antibody is washed over to create a sandwich of the analyte. (D) Magnetic nanotags bind to the biotinylated antibody to allow for quantitative detection. Reprinted with permission from reference (101) Osterfeld, S. J.; Yu, H.; Gaster, R. S.; Caramuta, S.; Xu, L.; Han, S.-J.; Hall, D. A.; Wilson, R. J.; Sun, S.; White, R. L.; Davis, R. W.; Pourmand, N.; Wang, S. X. Multiplex protein assays based on real-time magnetic nanotag sensing. *Proc. Natl. Acad. Sci.* **2008**, *105* (52), 20637–20640. Copyright 2008, National Academy of Sciences, U.S.A

MFnS synthesis and dual-mode detection of *E. coli* O157:H7

Figure 3:

Iron oxide nanoparticles functionalized into MFnS with conjugated antibody and DiI dye when incubated with bacteria allows for the quantitative detection of the bacteria through magnetic resonance and optical detection. Reprinted with permission from reference (55) Banerjee, T.; Sulthana, S.; Shelby, T.; Heckert, B.; Jewell, J.; Woody, K.; Karimnia, V.; McAfee, J.; Santra, S. Multiparametric Magneto-fluorescent Nanosensors for the Ultrasensitive Detection of *Escherichia coli* O157:H7. *ACS Infect. Dis.* **2016**, 2 (10), 667–673. Copyright 2016, American Chemical Society.

Figure 4:

(A) H3N2/Panama was detected using DRELFA but did not cross react with the subtypes H3N2/Udorn and H3N2/Aichi, unlike (B) the antibody-LFA which cross reacted with the other subtypes. Reprinted from reference (123) Le, T. T.; Chang, P.; Benton, D.; John, W.; Iqbal, M.; Edward, A.; Cass, G. Dual Recognition Element Lateral Flow Assay (DRELFA) - Towards Multiplex Strain Specific Influenza Virus Detection. *Anal. Chem.* **2017**, *89*(12), 6781–6786, under open access license CC-BY.

Figure 5:

Visual representation of a lateral flow type assay utilized to detect H1N1. The specimen is allowed to flow down the strip and the bioconjugate binds to the viral particles while the viral particles bind to the test line, creating a sandwich type interaction. Reprinted from reference (124) Yeo, S.; Choi, K.; Cuc, B. T.; Hong, N. N.; Bao, D. T.; Minh, N. Smartphone-Based Fluorescent Diagnostic System for Highly Pathogenic H5N1 Viruses. *Theranostics* **2016**, 6 (2), under open access liscence CC BY-NC.

Information about optical-based POC tests being developed including technique, target pathogen, LOD, timeliness, and any additional features mentioned in the study.

Table 1:

Technique	Target Pathogen	LOD	Speed	Additional features	Citation
Quantum dot fluorescence polarization analysis using bifunctional aptamer binding	Influenza (H1N1 DNA)	Detection limit: 3.45 nM	NR	Detects DNA sample so prep is needed. Not real sample.	Zhang et al. ³³
Strand displacement amplification with fluorescence polarization	<i>M. tuberculosis</i>	1 genome	3 h	Detected DNA isolated from culture, sample prep required.	Walker et al. ³⁴
Strand displacement amplification with fluorescence polarization	<i>M. tuberculosis</i>	10 genomes	20 min	Detected DNA isolated from culture, sample prep required.	Walker et al. ³⁶
Fluorescent nanoparticle-based indirect immunofluorescence microscopy	<i>M. tuberculosis</i>	3.6E5 cells/mL	4 h	In mixed bacteria and spiked sputum samples	Qin et al. ³⁵
Fluorescence polarization-based nucleic acid detection	<i>Salmonella spp.</i>	1 CFU	20 min	Can differentiate between <i>S. Typhi</i> and <i>S. Paratyphi</i> in blood samples. Cost: \$1.	Park et al. ³⁰
Fluorescence polarization immunoassay	<i>Brucella spp</i>	NR	5 min	Specificity 97.9% and sensitivity 96.1%. Detects in serum.	Lucero et al. ³⁷
Localized SPR-based AuNP-alloyed quantum dot nanobiosensor	Influenza (H3N2)	H3N2: 10 PFU/mL	5 min	Differentiated between H3N2 and H7N7/H9N2. Detection in water and human serum.	Takemura et al. ⁴¹
	Influenza (H1N1)	H1N1: 0.03 pg/mL in water and 0.4 pg/mL in human serum			
Quantum dot barcode technology with smartphones and isothermal amplification	HIV or hepatitis B	1000 viral genetic copies per milliliter	1 h	Can detect multiple pathogens at once. Detects amplified DNA so sample prep needed.	Ming et al. ⁴²
Nanobioprobes utilizing fluorescent quantum dots	Avian influenza virus (H9N2)	8.94 ng/mL	NR	Utilizes <i>S. Aureus</i> to make the nanobioprobes.	Xiong et al. ⁴³
Integrated portable microsystem with PCR amplification and capillary electrophoretic analysis coupled with electrical control and laser-excited fluorescence detection	<i>E. coli</i> and <i>S. Aureus</i>	2–3 bacterial cells	10 min	Detected cells suspended in water	Lagally et al. ⁴⁷
Microfluidic chip with integrated PCR and electrophoretic analysis	BK virus	1–2 viral copies	NR	Identifies viral loads. Detected PCR product from urine samples.	Kalgala et al. ⁴⁹
Bead-based immunofluorescence-assay on a microfluidic dielectrophoresis platform	Dengue	1E4 PFU/mL	5 min	Chip is reusable >50x.	Iswardy et al. ⁶⁰
Microfluidic chip capable of performing DNA/RNA amplification, electrokinetic sample injection and separation, and on-line optical detection of nucleic acid products	<i>S. pneumoniae</i> and Dengue-2 virus	NR	<5 min	-	Huang et al. ⁵¹
Microfluidic device integrated with microvalves and micropumps for rapid DNA hybridization using shuttle flow	4 serotypes of Dengue	100 pM	90 s	Sample consumption of 1 microliter. Could differentiate between the 4 sero types of dengue. Detect each simultaneously.	Huang et al. ⁵²

Technique	Target Pathogen	LOD	Speed	Additional features	Citation
Magnetic immunofluorescence assay using portable device equipped with optical fiber spectrometer and a microfluidic device	Avian influenza (H9N2)	3.7E4 copy/ μ L	55 min	Sample consumption of 2 microliters. Complex biological samples including fresh dung, liver, and lung. Differentiated H9N2 vs H5N1/H1N1.	Zhang et al. ⁴⁶
On-chip pressure injection utilizing DNA amplification via non-contact infrared-mediated polymerase PCR and microchip electrophoresis.	<i>S. typhimurium</i>	<1000 starting copies of DNA	12 min	Detected amplified DNA	Easley et al. ⁵³
Microfluidic integration of nanoplasmonic biosensor composed of a microarray of gold nanohole sensors	<i>C. trachomatis</i> and <i>N. gonorrhoeae</i>	Chlamydia trachomatis: 300 CFU/mL Neisseria gonorrhoeae: 1500 CFU/mL	< 1 h	Simultaneous detection in urine samples	Soler et al. ⁵⁴
Plastic-chip-based magnetophoretic immunoassay using magnetic and gold nanoparticles modified with <i>M. tuberculosis</i> antibodies	<i>M. tuberculosis</i>	1.8 pg/ml	1 h	Detection in sputum. Can differentiate between other mycobacterium. Cost <\$2 per assay	Kim et al. ⁵⁷
Glass chip optical analytical system developed by integrating microarray and fabricating gold nanoparticles	Avian Influenza (H5N1 and H9N2)	1 pg/mL	NR	-	Park et al. ⁶¹
Dual-molecular affinity-based Förster (fluorescence) resonance energy transfer platform using fluorescent vancomycin-gold nanoclusters and aptamer-gold nanoparticles	<i>S. aureus</i>	10 CFU/mL	30 min	The limit of detections in the diluted milk, orange juice, and human serum sample for <i>S. aureus</i> are 300, 100, and 100 cfu/mL	Yü et al. ⁵⁹

Information about electrochemical-based POC tests being developed including technique, target pathogen, LOD, timeliness, and any additional features mentioned in the study.

Table 2:

Technique	Target Pathogen	LOD	Speed	Additional Features	Citation
Nanowire field effect transistors using nanowire arrays modified with antibodies for influenza A	Influenza and adenovirus	50 virions/microliter	NR	Can detect two viruses in parallel	Patolsky et al. ⁶⁸
Glycan-immobilized field effect transistor (FET) biosensor	Influenza	60 H5 HA molecules and 6000 H1 HA molecules in 20 μ L samples	NR	Can differentiate between H1 and H5	Hideshima et al. ⁶⁶
Direct potentiometric serological diagnosis using extended-gate field-effect transistor containing MOSFET transducer and gold-coated chip	Bovine Herpes Virus-1	1:100 serum dilution	10 min	Detection in serum.	Tarasov et al. ⁷⁰
Portable graphene-enabled biosensor using specific immobilized monoclonal antibody	Zika	450 pM	5 min	-	Afsahi et al. ⁷¹
Multiplexed detection of bacterial cells with microfluidic chip using antimicrobial peptides	<i>S. mutans</i> and <i>P. aeruginosa</i>	1E5 CFU/mL	25 min	-	Lillehoj et al. ⁷⁴
Bead based microfluidic chip detection using voltammetry and paramagnetic beads made with CdS quantum dots	Influenza (H5N1)	NR	45 min	-	Krejcová et al. ⁷⁵
Label-free detection using microfluidic chip integrated with an RGO-based electrochemical immunosensor	Influenza (H1N1)	0.5 PFU/mL	15 min	-	Singh et al. ⁷⁶
Micro-fluidic detector which employs a high-gradient magnetic field, on-chip RT-PCR, single-stranded DNA generation, and sequence-specific E-DNA detection.	Influenza (H1N1)	10 TCID50	3.5 h	Detection from throat swabs	Hsieh et al. ⁴⁴
Electrochemical DNA sensor in a microfluidic chip format with loop-mediated isothermal amplification	<i>S. enterica</i> subsp. <i>enterica</i> serovars <i>Typhimurium</i> and <i>Choleraesuis</i>	6.9×10^4 CFU/mL	2 h	Detection in whole blood and could differentiate between <i>S. typhimurium</i> and <i>S. choleraesuis</i>	Hsieh et al. ⁴⁴
Microfluidic electrochemical platform with loop-mediated isothermal amplification	<i>Salmonella</i> genomic DNA	16 copies	50 min	Can determine viral load	Hsieh et al. ⁴⁴
Microfluidic immunosensor with Cholera toxin subunit B (CTB)-specific antibodies immobilized onto superparamagnetic beads	Cholera toxin	9.0 ng/mL	1.5 h	Detection in fecal samples	Bunyakul et al. ⁷⁷
Differentiation of bacteria using multiplex microfluidic chip with on chip loop-mediated isothermal amplification	<i>M. tuberculosis</i>	28 copies/ μ L	45 min	Detection in bacteria culture samples	Luo et al. ⁹³
	<i>H. influenza</i>	17 copies/ μ L			
	<i>K. pneumonia</i>	16 copies/ μ L			
Nano-electrochemical technique using silver nanoparticles	influenza	Single virus	NR	-	Sepunaru et al. ⁶⁵
Electrochemical bioassay using colloidal gold nanoparticles	<i>M. Tuberculosis</i>	1 CFU	90 min	Can be done using a portable potentiostat	Ng et al. ⁹⁴
Electrochemical aptasensor developed using coil-like fullerene-doped polyaniline, gold nanoparticles and aptamers	<i>M. Tuberculosis</i> (MPT64)	20 fg/mL	NR	Detection in human serum	Bai et al. ⁸²

Technique	Target Pathogen	LOD	Speed	Additional Features	Citation
Electrochemical immunoassay using layer-by-layer coating carbon nanotubes and graphene oxide as a nanocarrier	<i>C. difficile</i> (toxin B)	0.7 pg/mL	45 min	Detection in human stool samples	Fang et al. ⁸³
Electrochemical capacitive sensing	Dengue, zika, and chikungunya (NS1)	0.5 ng/mL	NR	Detection in serum	Cecchetto et al. ⁸⁴
Impedimetric glycan-based biosensor	Influenza H3N2	13 viral particles in 1 µl	NR	Differentiation shown between H3N2 and H7N7	Hushgyi et al. ⁸⁵
Label free electrochemical immunosensor using an anti-ESAT-6 monoclonal antibody	<i>M. tuberculosis</i> (ESAT-6)	7 ng/mL	NR	Can discriminate between culture filtrate proteins from pathogenic mycobacteria strains and BCG non-virulent mycobacteria vaccine strain.	Diouani et al. ⁹⁵
Electrochemical DNA hybridization biosensor using a gold nanotubes array electrode platform	<i>M. tuberculosis</i>	0.05 ng/µL	NR	-	Torati et al. ⁸⁹
Electrochemical detection using multifunctional nanoconjugates and subsequent signal amplification	<i>E. coli</i> O157:H7	39 CFU/mL	NR	Can detect 2 types of bacteria simultaneously	Li et al. ⁹⁰
	<i>V. cholera</i> O1	32 CFU/mL			
Label-free biosensor using faradaic electrochemical impedance spectroscopy	<i>E. coli</i>	1E2 to 1E3 CFU/mL	30 min	-	Guo et al. ⁸⁷
Electrochemical detection using allosteric enzymes and coulometry.	Anti-HIV antibodies	4µM	1 h	Detection in serum	Laczka et al. ⁹¹
Label-free electrochemical sensor using streptavidin-coated magnetic beads	HIV-1 (subtypes A, B, C, D, E, and G)	1.17 × 1E8 –8.39 × 1E8 copies/mL	30 min	-	Shafiee et al. ⁸⁶
Thin-film transistor nanoribbon sensor	<i>E. coli</i> and <i>K. pneumoniae</i>	<10 copies of genomic DNA	5 min	-	Hu et al. ⁹²

Table 3:

Information about magnetic-based POC tests being developed including technique, target pathogen, LOD, timeliness, and any additional features mentioned in the study.

Technique	Target Pathogen	LOD	Speed	Additional features	Citation
Magnetic relaxation nanosensor detection using ironoxide nanoparticles	Influenza (H5N1 and H1N1)	1 nM	<30 min	Differentiation shown between H5N1 and H1N1	Shelby et al. ¹¹⁶
Magneto-Fluorescent nanosensors detection utilizing changes in T2 relaxation time	<i>E. coli</i>	1 CFU	30 min	-	Banerjee et al. ⁵⁵
Magnetoresistive biosensor	BCG bacteria	1E4 cells/mL	NR	-	Barroso et al. ¹⁰⁹
Giant magnetoresistance biosensor using monoclonal antibodies and magnetic nanoparticles	Influenza	1.5E2 TCID50/mL virus	1 min	-	Krishna et al. ¹⁰³
Detection using loop-mediated isothermal amplification, AC susceptometry, and magnetic nanoparticles	Zika virus oligonucleotide	1 aM	27 min	Detection in 20% serum. Can use a portable AC susceptometer.	Tian et al. ¹¹⁰
AC magnetic field detection method using oligonucleotide-tagged magnetic beads	<i>V. cholera</i> DNA	10 pM	60 min	-	Bejhed et al. ¹¹¹
Blu-ray optomagnetic detection	<i>S. typhimurium</i> and <i>E. coli</i>	8E4 CFU/mL	3 h	Can simultaneously detect <i>S. typhimurium</i> and <i>E. coli</i>	Tian et al. ¹¹²
Detection using handheld diagnostic magnetic resonance system	<i>S. aureus</i>	10 bacteria in a 10- μ l sample	<15 min	-	Lee et al. ¹¹³
Microchip-based sensor using magnetic bead bioassay platform	Dengue (anti-dengue virus IgG)	100 pg/ml	NR	-	Aytur et al. ¹¹⁵
Magnetic barcoding detection by nuclear magnetic resonance	<i>M. tuberculosis</i>	1E3 cells/mL	2.5 h	One-time equipment cost: \$4,300 Per assay: \$3 Detection in spiked sputum	Liong et al. ¹¹⁴

Table 4:

Information about colorimetric-based POC tests being developed including technique, target pathogen, LOD, timeliness, and any additional features mentioned in the studies.

Technique	Target Pathogen	LOD	Speed	Additional features	Citation
Lateral flow test using nitrocellulose membrane and adsorbed onto colloidal gold particles to	<i>M. tuberculosis</i>	NR	15 min	Sensitivity and specificity >90%	Gonzalez et al. ¹²²
Lateral flow assay which pairs a nucleic acid aptamer with an antibody	Influenza	2E6 viral particles	15 min	Can differentiate between subtypes	Le et al. ¹²³
Smartphone-based fluorescent diagnostic device	Influenza	H7N1: 5.34E2 PFU/mL H9N2: 1.37E1 PFU/mL	15 min	H5N1 Sensitivity: 96.55% Specificity: 98.55%	Yeo et al. ¹²⁴
Lateral flow biosensor using loop-mediated isothermal amplification and gold nanoparticles	<i>E. faecalis</i>	710 CFU/mL	75 min	Detection in spiked blood samples	Wang et al. ¹²⁵
	<i>S. aureus</i>	680 CFU/mL			
Displacement amplification label-based gold nanoparticles lateral flow biosensor	<i>L. monocytogenes</i>	10 fg of genomic templates per reaction in pure culture	1 h	Detection in pork samples. One time equipment cost: \$600 USD Per assay: \$6	Wang et al. ¹²⁶
Later flow assay using label-based gold nanoparticles with a multiple cross displacement amplification technique	Shigella	10 fg of genomic templates per reaction in pure culture and 5.86 CFU per tube in human fecal samples	1 h	Detection in human fecal samples	Wang et al. ¹²⁷
Multiplex LAMP label-based lateral flow dipstick biosensor using gold nanoparticles	<i>Leptospira</i>	3.95 × 1E-1 genomic equivalent per reaction [Fig.]	1 h	-	Nurul Najian et al. ¹²⁹
Lateral flow assay using multicolored silver nanoparticles	Dengue, yellow fever, and ebola virus	150ng/mL	NR	Can differentiate between dengue, yellow fever, and ebola viruses.	Yen et al. ¹²⁸
Naked-eye detection of nucleic acids using isothermal amplification and magnetic particle mediated aggregation	human papillomavirus	5.1 amol	60–120 min	Detection in blood sample	Lin et al. ¹³⁰
Label-free dual fluorescence for the visual product detection isothermal multiple-self-matching-initiated amplified DNA	hepatitis B virus	10 copies of DNA	NR	-	Ding et al. ¹³¹
Visual gene-detecting technique using nanoparticle gene probes and silver staining enhancement	Hepatitis B and C viruses	Hepatitis B: 3.6E-11 M Hepatitis C: 3.6E-10 M	3 h	-	Wang et al. ¹³²
Colorimetric assay that utilizes the chemical oxidation of 3,3', 5,5'-tetramethylbenzidine by isothermally functionalized DNA targets	<i>M. tuberculosis</i>	1 CFU	75 min	Cost: \$3 per assay	Ng et al. ¹³³
Probe-based colorimetric assay using gold nanoparticles	<i>M. tuberculosis</i>	0.75 µg of DNA	2 h	Cost: \$0.35 per sample Detection in sputum, bronchial washes, pleural effusion, urine, and blood	Baptista et al. ¹³⁴

Technique	Target Pathogen	LOD	Speed	Additional features	Citation
Dipstick visual detection using gold nanoparticles and aptamers	Influenza	3E8 viral particles	NR	-	Le et al. ¹³⁵
Multiplexed kit capable with target-specific fluorescently tagged strand displaceable probes with RT-LAMP	Zika	~0.71 pfu equivalent viral RNAs	30 min	Detection in urine and plasma	Yaren et al. ¹³⁶
	Dengue	~1.22 pfu equivalent viral RNAs,			
	Chikungunya	~38 copies of viral RNA			
Immunochromatography dipstick test using monoclonal antibodies	Dengue and Zika	NR	1 h	Distinguishes between the four dengue serotypes and Zika. Detection in serum. Dengue sensitivity/specificity: ranges from 76% to 100%. Zika sensitivity/specificity: 81/86%	Bosch et al. ¹³⁹